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Abstract
Targeting Vulnerabilities in Cell State and Calcium Signaling for the Treatment of Lung Cancer
Clark A. Jones
Lung cancer remains the deadliest of all cancers due to the high mutational burden associated
with the disease. Combating mutational drivers and drug resistance proves to be essential in
the development of novel therapies to improve patient outcomes. A first-in-class cyclic peptide
known as MTI-101 has been shown to induce necrotic cell death in a caspase independent
manner. MTI-101 was derived from the linear peptide known as HYD1 that was found in a high
throughput screen to block cell adhesion with the extracellular matrix. The compound was
further optimized and cyclized to the currently used MTI-101 that was found to be substantially
more potent across multiple cancer types. In this dissertation, we sought to determine
biomarkers of resistance to MTI-101 coupled with cell signaling pathways that become
activated with the introduction of MTI-101 along with their contribution to cell death. The
development of isogenic resistant lung cancer cell lines were utilized as tools to aid in the
delineation of MTI-101’s effects on lung cancer. Chronic exposure to MTI-101 leading to the
acquired resistance demonstrated changes of cell state to a clinically favorable mesenchymalto-epithelial transition (MET) genotype and phenotype using in vitro and in vivo models.
Selectivity of MTI-101 towards cancer cells was revealed with a lack of efficacy in healthy
bronchial epithelial cells treated with a lethal cancer cell dose of MTI-101. Acquired resistance
was found to have collateral sensitivity to standard of care agents while used as single agents
and synergistic activity on wildtype cancer cells when used in combination with MTI-101.
Simultaneous activation of second messengers calcium and cAMP alluded toward GPCR
activation with MTI-101 treatment. Attenuation of calcium signaling protected from MTI-101
induced cell death while activation of calcium signaling exacerbated death. Decreased drug
binding likely explained the lack of downstream signaling and protection from cell death in
acquired resistant lung cancer cell lines. Incorporation of therapies that alter cell state and
calcium signaling pathways in combination with current standard of care agents remain vital in
positioning novel therapy options in the clinic for improved patient survival with the deadliest
cancer.
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Chapter 1

Introduction and Literature Review
Lung Cancer
Lung cancer remains the leading cause of cancer related death that accounts for more
deaths each year than colon, breast and prostate cancer combined[1]. The disease is
characterized by a high mutational burden that includes some of the more common driver
mutations such as ALK, EGFR, and KRAS[2]. The prominent cause of lung cancer originates from
smoking tobacco products and its most common presentation occurs in people over the age of
65. Other risk factors can come from environmental factors such as exposure to radon,
asbestos, air pollution and water supply contamination with arsenic[1]. Lung cancer effects are
seen equally among genders, despite difference among races with African descents at
disproportionately higher rates[3]. The disease is broken into two classes of diagnosis either
being non-small cell lung cancer (NSCLC) which makes up about 85% of all cases, and small cell
lung cancer (SCLC) which makes up about 15% of cases[1]. NSCLC is further divided into three
subsections known as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The survival rate remains dependent on the stage in which the cancer is diagnosed.
Unfortunately, the majority of all new lung cancer cases are diagnosed at stage IV where the
cancer has metastasized to multiple sites within the body with a five year survival at a dismal
1%[4]. Advancements in technology for earlier detection methods along with novel therapies
aim to improve these statistics for treatment in the future.
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The treatment for lung cancer is separated among the clinical presentation between
NSCLC and SCLC along with the tumor stage. SCLC gets divided between a limited and an
extensive stage. Limited stage SCLC can typically be treated with radiation coupled with
chemotherapy while extensive stage SCLC are mostly treated with just chemotherapy to limit
the progression but not cure the patient[5]. NSCLC has a more complex staging system as
treatment options become more abundant for this subset of lung cancers. The TNM staging
system is still used to identify the location(s) in which the tumor exists as either solely in the
primary tumor site (T), spreading of the tumor to nearby lymph nodes (N) or metastasis to
distal sites in the body (M). Additional staging within these groups is also used to further
delineate the tumor characteristics and is broken into four substages. Stage I deals with a
tumor only in the primary site under 5 cm, Stage II has the tumor spread to nearby lymph
nodes, Stage III describes the tumor that has migrated to the center of the chest along with the
lymph nodes, while Stage IV has metastasized to other parts of the body[6]. Stages I-III typically
combine surgical removal of the primary tumor coupled with radiation and chemotherapy in
attempt to prevent recurrence. Stage IV treatment options consist mostly of chemotherapy
coupled with palliative care therapies unless the tumor contains markers that would suggest
success in targeted therapies[7]. Recently, formidable advances have been made in targeted
therapy for lung cancer. All lung cancers are sequenced at the time of diagnosis for markers
that could correlate to responsiveness to current targeted therapy options. As stated before,
one of the most common mutations in lung cancer is an epidermal growth factor receptor
(EGFR) mutation that causes this receptor to be constitutively active. Tyrosine kinase inhibitors
(TKIs) have been developed to selectively target this mutated EGFR present on cancer cells
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while leaving healthy normal cells undisturbed. Frontline TKIs such as erlotinib have been
developed to target these mutations and have improved patient survival on average 2 months
and up to 8 years in the most extreme cases for late stage NSCLC[8]. In addition, third
generation TKIs such as Osimertinib have been developed to target the most common TKI
resistant mechanism T790M mutation to further improve survival outcomes from first and
second generation TKIs by over 9 months progression free on average[9]. Furthermore, huge
milestones have been breached within the last year as the first FDA approved drug targeting a
KRAS mutation was developed known as sotorasib[10]. The incorporation of immunotherapies
for the treatment of lung cancer has been on the rise for further therapy options. Currently,
PD-L1 inhibitors remain at the forefront of immunotherapy options for NSCLC[11]. Despite the
breadth of options for therapy, tumor heterogeneity proves to be a difficult hurdle to overcome
in prevention of recurrence where therapy eventually fails. New combination strategies,
advancements in detection methods, and novel drugs are vital for improved patient outcomes.

MTI-101
The peptide MTI-101 was originally derived from a parent compound known as HYD1
that was discovered in a high throughput screen to block cell adhesion to the extracellular
matrix (ECM)[12], [13]. HYD1 is a 10 D-amino acid with the following sequence: KIKMVISWKG.
As a single agent, it was also found to induce necrotic cell death via reduction in mitochondria
membrane potential along with an increase in reactive oxygen species[14]. HYD1 was found to
induce cell death independent of apoptosis explained by the absence of caspase activation[14].
Through further experimentation, the minimally active core of HYD1 was found to be MVISW.
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To enhance potency, the peptide was cyclized using a b turn promoter scaffold backbone and
the sequence was further modified to include three lysine residues on the non-recognition
strand to improve water solubility to the optimized cyclic peptide known as MTI-101 with the
following backbone sequence: NLeVVAW[15]. The full peptide is shown in Figure 1. MTI-101
was found to be substantially more potent than HYD1 and have anti-tumor effects across
multiple cancers in vitro and in vivo including castrate-resistant prostate cancer and multiple
myeloma[16], [17]. MTI-101 will be analyzed throughout this dissertation to investigate its
potential role in the treatment of lung cancer.

Epithelial-to-Mesenchymal Transition
Non-cancerous cells undergo a transition that allow them to move and expand for
normal physiological functions such as wound healing and development[18]. Cancer has found
a way to hijack this transition in order to grow and metastasize to other parts of the body when
resources become limited at the primary tumor site across multiple tumor types including but
not limited to breast, prostate, and lung cancer[19]–[21]. This process is known as the
epithelial-to-mesenchymal transition (EMT) illustrated in Figure 2. Epithelial like cells have high
expression of tight junction proteins such as claudins, occludins, and E-cadherin that are utilized
for cell-cell connections along with attachment to the basement membrane[22], [23]. This cell
state has been shown to have enhanced sensitivity to anoikis by interaction with E-cadherin
complexes which control the balance of survival or apoptosis based on connections from the
basement membrane and adjacent cells[24], [25]. A mesenchymal phenotype consists of
characteristics such as elongated motile cells that have greater resistance to anoikis[24].
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Increased expression of proteins that allow for motility within the ECM such as Fibronectin, NCadherin, and Collagen give mesenchymal cells some of the necessary tools to invade and
metastasize throughout the body[26], [27]. Cancer cells undergo EMT through stress stimuli
that alter cell state by reducing epithelial like proteins and increasing mesenchymal proteins by
means of survival. Common sources of induction of EMT include limited nutrients in the tumor
microenvironment[28], [29], immune surveillance[30], along with drug treatment[31].
Unfortunately, lung cancer treatment with standard of care agents often induces a drug
resistant phenotype that has undergone EMT[32], [33]. This EMT phenotype has become
increasingly difficult to treat as it develops multidrug resistance in the clinic[34]. Targeting cell
state may prove to be just as important as inducing cell death in cancer cells. Understanding
commonalities between therapies that alter cell state will be vital in the treatment of these
late-stage metastatic cancers.

Calcium Homeostasis
Calcium is tightly regulated within cells as it is essential for many physiological and
pathological functions. Given its wide role in cellular functions, cells have intracellular calcium
stores in order to have the resource readily available at a moment’s notice. The main location
of intracellular calcium stores resides in the endoplasmic reticulum(ER)[35]. Sarco/Endoplasmic
Reticulum Calcium ATPases (SERCA) are pumps that allow for cytoplasmic calcium to be
shuttled against the concentration gradient into the ER to stock calcium up to a concentration
of 1-2 mM despite resting cytoplasmic concentrations averaging around 100 nM[36]. Calcium is
released from the ER by means of IP3 receptors or ryanodine receptors controlled by direct
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levels of IP3 and cyclic ADP ribose respectively[37]. IP3 is generated as a downstream signaling
messenger of the Phospholipase C (PLC) pathway that is commonly activated by G-Protein
Coupled Receptors (GPCRs) and Receptor Tyrosine Kinases (RTKs). Ryanodine receptors are
directly modulated by calcium concentrations in the ER and cytoplasm. These ryanodine
receptors can open in response to low cytoplasmic calcium levels as well as extremely high
concentrations of ER calcium to prevent cell death[37].
While the ER serves as the main intracellular storage of calcium, the mitochondria has
been shown to participate in cytoplasmic calcium buffering[38]. Calcium is transported into the
mitochondria via the mitochondrial calcium uniporter (MCU). The mitochondria use calcium
ions for the augmentation of ATP production[39], but have recently been shown to buffer
cytoplasmic calcium levels[40]. The ER and mitochondria work in coordination with many
enzymes and receptors to tightly regulate one of the most important second messengers in
cells to organize cell signaling essential for survival.
Furthermore, intracellular calcium can regulate calcium levels by binding to enzymes such as
calmodulin. Calmodulin is involved in a plethora of functions and has been shown to modulate
enzymes, receptors and entire signaling pathways[41]. The activation of calmodulin occurs
when intracellular calcium levels rise and bind to the four calcium binding pockets on the
molecule transforming the protein into its active conformation[42]. The ER is able to
communicate with the store operated calcium entry (SOCE) that exists as various receptors on
the plasma membrane such as ORAI1 and TRPC that allow for the transport of extracellular
calcium into the cell. When calcium stores are low in the ER, STIM1 dimerizes on the ER
membrane and communicates with the SOCE channels on the plasma membrane to influx
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extracellular calcium into the cytoplasm[43]. This signal can be terminated by calcium being
restored in the ER and preventing STIM1 from dimerizing, causing the closing of the SOCE[44].
Calmodulin has also been shown to negatively regulate the IP3 receptors on the ER
membrane[45] as well as SOCE channels such as TRPC1[46]and ORAI1/STIM1 complex[47]
when bound to calcium in its active conformation. Voltage gated calcium channels (VGCC) have
their own variation of calcium regulation, but given lung cancer is a non-excitable cell, this
dissertation will focus on calcium homeostasis around ligand gated calcium channels (LGCC).
Cancer cells modulate the calcium homeostasis pathway in order to survive and
proliferate. Cell alterations consistent with malignancies include changes in receptors,
enzymes, and tolerance/utilization of calcium within cells. Different types of cancer were
shown to overexpress SOCE channels such as ORAI1, TRPC, and TRPV to accommodate an
excessive need for calcium to allow malignant cells to divide rapidly and metastasize[48]. The
knockdown expression of the MCU has been shown to decrease metastasis and invasion in
breast cancer cells illustrating its potential role in tumorigenesis [49]. The calcium dependent
enzyme calmodulin has also been shown to be involved with invasion while pharmacological
inhibition of calmodulin has been shown to decrease cell motility and metastasis in cancer[50].
In addition, calmodulin overexpression in multiple tumor types including breast and [51] lung
cancer [52] may explain this contribute to cancer progression and invasion. Further research is
warranted to better incorporate calcium signaling in cancer treatment given its vast role in
cellular functions. The role of calcium homeostasis in cancer progression and current strategies
to target these pathways will be discussed further in Chapter 2 of this dissertation.
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GPCR Signaling
G-Protein coupled receptors (GPCRs) are the most abundant family of membrane
proteins responsible for a plethora of cell responses and regulations including but not limited to
sensation, metabolism, immune response, motility and growth[53]–[56]. GPCRs exist as 7transmembrane domain proteins that span the width of the plasma membrane[57]. There are
over 1000 different GPCRs and each is specific to a particular ligand and cellular response[58].
Some examples of GPCR ligands include light energy, peptides, lipids, sugars, and proteins.
There are approximately 100 GPCRs that currently do not have known ligands and are known as
orphan GPCRs[59]. These cell surface receptors are linked to G-proteins on the intracellular
domain that are responsible for signal transduction within cells. The G-proteins consist of an
alpha (a), beta (b) and gamma (g) subunit that form a heterotrimeric complex. Activation of
the GPCR causes a conformation change that allows the G-protein complex to exchange GDP
for GTP at the intracellular G-protein a subunit which causes the dissociation of the b and g
subunits from the complex and the a subunit[57]. The a subunit is the main signal transducer,
but the bg dimer has been shown to be involved in the negative regulation of a along with
various ion channels[60], [61]. The full activity of signal transduction with the bg dimer is still
not fully understood. The better characterized signaling subunits of GPCRs is the a subunit that
has been grouped into four different classes as follows: Gaq, Gas, Gai, and Ga12/13. The signaling
pathway for the three most common subunits is shown in Figure 3. Each class of a subunits
contain multiple isoforms but the high sequence homology within each respective class
activates the same downstream effector molecules. The Gaq is capable of activating the
Phospholipase C (PLC) signaling pathway that utilizes calcium as a second messenger for its
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cellular effect[62]. The Gas and Gai work in opposition of each other as Gas activates adenylyl
cyclase (AC) that utilizes cyclic adenosine monophosphate (cAMP) as a second messenger while
Gai negatively regulates AC to decrease cytosolic cAMP[63]. Ga12/13 primarily target Rho
guanine nucleotide exchange factor (Rho-GEF) which can activate rho-associated protein
kinases (ROCKs) as secondary messengers to modulate cell functions[64]. The main role of
Ga12/13 has been described as rearrangement of cytoskeletal elements in excitable cells[65].
Also, all known Ga12/13 subunits are coupled with additional a subunits that primarily signal
through the other subunit[65]. All GPCRs contain at least one a, b, and g subunit despite the
numerous combinations of different isoforms coupled in each intracellular domain. The GPCR
can be linked with any combination of the four a family subunits as well (ranging from 1 to all
4) producing extremely diverse signals with each respective GPCR[66]. The most recent
classification system has GPCRs divided among the following groups based on sequence and
functional similarities: glutamate, rhodopsin, adhesion, frizzled/taste, and secretin[67]. Despite
the differences of each class, all GPCRs are regulated by common factors.
The negative regulation of GPCR signaling remains vital for properly executing functions
and tasks, given their wide role in cellular processes. Prolonged signaling is capable of inducing
cellular stress, mutations, and even cell death[68]. GPCRs rely on multiple factors for proper
signal transduction and termination in order to function correctly. GTPases mediate all GPCR
signals by hydrolyzing GTP back to GDP on the a subunit which favors the reassociation of the
G-protein heterotrimeric complex with the GPCR[69]. Given this process is extremely slow,
GPCR signals are often regulated by additional proteins. Regulators of G-protein signaling (RGS)
allosterically modulate GTPases by accelerating the conversion of GTP to GDP to expedite the
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termination of signal[69]. Sustained agonist binding to GPCRs induces receptor endocytosis via
phosphorylation of the GPCR by GPCR kinases (GRKs) and coupling to b-arrestin scaffolding
proteins[70]. Receptor endocytosis desensitizes the receptor from agonist stimulation and
further signal transduction. The receptor can later be degraded internally by lysosomes or
trafficked back to the plasma membrane for future ligand activation[71]. Activation of
downstream effectors such as PKC and PKA have been shown to phosphorylate GPCRs
regardless of ligand binding to stop further signaling of activated GPCRs along with the
impedance of new receptor signaling[70]. GTPases, RGSs, GRKs, and downstream effector
molecules all work in concert to relay stimuli messages properly with each GPCR. Given GPCRs
are involved in many pathological cases, understanding how to modulate GPCR regulators may
prove to play a pivotal role in drug development for disease states. Further information is
provided on the role of GPCRs in cancer progression along with targeting strategies for novel
therapies in Chapter 2 of this dissertation.
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Figure Legends
Figure 1. Chemical structure of MTI-101
Figure 2. The transient epithelial-to-mesenchymal transition (EMT). Epithelial cells have high
expression of tight junction proteins such as E-cadherin, claudin, and occluding. Loss of tight
junction proteins coupled with increases in mesenchymal proteins such as TWIST, fibronectin,
and vimentin cause loss of cell polarity along with extracellular matrix (ECM) remodeling
leading to elongation of cells. Release of matrix metalloproteases (MMPs) allows for the final
step in the EMT process in which cells gain the ability to invade in the ECM and metastasize in
the body.
Figure 3. The three main signal transduction pathways in non-excitable cells of the G-protein
coupled receptor (GPCR) Ga subunit. GPCR ligands bind to their respective GPCR to induce a
conformation change creating an exchange of GDP to GTP at the Ga subunit. Gas (green)
activates adenylyl cyclase which uses cAMP as a second messenger along with Protein Kinase A
(PKA) for cellular response while Gai (orange) inhibits this process. Gaq (blue) activates
Phospholipase C (PLC) that utilizes Inositol Triphosphate (IP3) and diacylglycerol (DAG) as
second messengers that increase cytosolic calcium and Protein Kinase C (PKC) respectively for
cellular response.
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Abstract
Calcium is essential for cells to perform numerous physiological processes. In cancer, the
augmentation of calcium signaling supports the more proliferative and migratory cells, which is
a characteristic of the epithelial-to-mesenchymal transition (EMT). By genetically and
epigenetically modifying genes, channels, and entire signaling pathways, cancer cells have
adapted to survive with an extreme imbalance of calcium that allows them to grow and
metastasize in an abnormal manner. This cellular remodeling also allows for the evasion of
immune surveillance and the development of drug resistance, which lead to poor prognosis in
patients. Understanding the role calcium flux plays in driving the phenotypes associated with
invasion, immune suppression, metastasis, and drug resistance remains critical for determining
treatments to optimize clinical outcomes and future drug discovery.

Introduction
Calcium is one of the most important elemental molecules in the human body;
therefore, its regulation is just as crucial. It plays a vital role in many physiological processes,
including, but not limited to, muscle contractions, metabolism, phagocytosis, apoptosis, cell
division, motility, and signaling [1,2,3,4]. Despite calcium’s expansive role within the body,
unbound, cytosolic-free calcium is the only form that can be used for physiological and
pathological functions. In order for cells to perform their everyday functions, adequate calcium
levels must be met and maintained, leading to the tight regulation of calcium throughout the
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body. Bones, therefore, act as reservoirs to store excess calcium for utilization when accessible
extracellular levels are insufficient in circulation.
Central to calcium homeostasis are the parathyroid hormone (PTH) and calcitonin.
When extracellular calcium is low in circulation, PTH is released by the parathyroid glands. This
triggers the release of calcium from bone deposits into the bloodstream and the inhibition of
calcitonin, a negative regulator of calcium [5]. On the other hand, calcitonin is activated when
calcium exceeds its narrow threshold, thereby causing the redeposition of calcium to the bone,
along with excretion by the kidneys [5]. Disease states, such as hypercalcemia and osteoporosis,
occur when the regulatory factors of calcium homeostasis are not able to function properly [6].
Prolonged uncontrolled fluctuations can lead to severe consequences, including neurological
problems, kidney failure, and even death.
In cancer cells, mutations and changes in the expression of calcium channels, pumps,
and binding proteins have resulted in calcium levels that exceed the typical threshold of normal
cells. These elevated calcium levels allow the cells to proliferate and become malignant [7].
Cells that gain the ability to break through the extracellular matrix (ECM) and metastasize to
distal portions of the body are said to undergo a process known as the epithelial-tomesenchymal transition (EMT). The many roles calcium plays in EMT are shown in Figure 1.
EMT is a slow, transient process that involves the deterioration of cell–cell junctions and
detachment from the basement membrane, where cells lose their polarity. In non-malignant
cells, EMT is common for functions such as wound healing, growth, and development.
However, in pancreatic, lung, and breast cancer cells, this malignancy process has been shown
to lead to poor prognosis and increased tumor progression [8,9,10]. Common epithelial genes
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that are downregulated for this transition include E-cadherin, claudins, and occludins, which are
essential in forming junctions between cells and holding them in place. Mesenchymal genes
that are upregulated include vimentin, N-cadherin, and matrix metalloproteases (MMPs), which
provide cells with some of the necessary tools to metastasize away from the primary tumor.
The reverse process of EMT is called mesenchymal-to-epithelial transition (MET). When
nutrients become scarce, cancer cells hijack both the EMT and MET processes to survive. These
cells use the EMT process to metastasize from the nutrient-deprived primary tumor and the
MET process to recolonize in a distal, nutrient-rich environment. In this environment, they
become epithelial, similar to cells attached to a basement membrane, and form cell–cell
junctions once more. In this review, the central role calcium plays in EMT are discussed in the
following areas: (1) Calcium Channels, (2) GPCR Signaling, (3) Interplay with Integrins, (4)
Immune Evasion/Drug Resistance, and (5) Combination Therapy.

Calcium Channels

In a resting cell, intracellular calcium levels remain close to only 100 nM. This is
substantially lower than extracellular calcium concentrations, which range from 1 to 2 mM [7].
Channels and pumps are responsible for maintaining such a tightly regulated concentration
within the cell, allowing for a chemical gradient across the cell membrane. The two types of
calcium channels that exist in cells are voltage-gated and ligand-gated. Voltage-gated calcium
channels (VGCC) cause an influx of calcium into excitable cells, such as neurons [11]. Typically, a
quick response is elicited by a VGCC, such as a neuronal signal relay or a muscle contraction. In
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contrast, ligand-gated calcium channels (LGCCs) induce calcium influx in all other non-excitable
cells, and usually generate a much slower and more prolonged effect, which can lead to either
cell proliferation or apoptosis, depending on the levels of calcium flux and the cellular context
[12]. The variety, localization, and abundance of these channels are tightly regulated, due to
their wide range of functionality in different cell types.
The LGCCs are the first step in a cellular process known as store-operated calcium entry
(SOCE). This is also the primary means by which malignant cells obtain calcium for cancer
progression [13]. Recent studies have shown that proteins such as STIM1, on the endoplasmic
reticulum (ER) membrane, and Orai1, on the plasma membrane, play an essential role in the
function of these channels. STIM1 is responsible for signaling to the plasma membrane after
cellular ER calcium stores are depleted [11]. Orai1 is utilized by the SOCE pathway via pore
formation in the plasma membrane, which selectively allows the passage of calcium ions [14].
Another ion channel that allows calcium fluctuations to occur is called a transient receptor
potential (TRP). The family of TRP channels is less selective than Orai1, and can allow the
passage of other cations, such as sodium, potassium, and magnesium [15]. The literature
supports the fact that both subtypes (TRPC and TRPV) are capable of forming complexes with
STIM1 and Orai1 to create sustained calcium entry [16,17]. The overexpression of a variety of
members from the TRP family has been correlated with increased EMT [18] and poor patient
prognosis [19,20].
The dysregulation of these proteins is often linked to multiple cancers, which show increased
production and localization to their respective membranes, to accommodate an increased need
for calcium. For example, it has been shown that the overexpression of STIM1 in hepatocellular
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carcinoma leads to increased cytoplasmic calcium and increased cellular proliferation [21]. In
addition, there is evidence to support the overexpression of Orai1 in lung cancer correlates with
increased cell proliferation, along with poor patient prognosis in the clinic [22]. Calcium
channels play the central role in calcium fluctuations in cells, but are not the only means of
initiating elevated cytosolic-free calcium. G-protein coupled receptors (GPCRs) are also capable
of altering intracellular calcium by means of coordination with SOCE and calcium channels along
with crosstalk among additional signal transduction pathways, such as receptor tyrosine kinases
(RTK) [23].

GPCR Signaling

GPCRs are involved in a plethora of physiological functions, such as the regulation of
behavior, the immune system, cell growth, motility, and sensory input [24,25,26,27].
Unfortunately, GPCRs are also involved in numerous disease states, including immune
deficiencies, mental and metabolic disorders, lack of sensation, and cancer [28,29,30]. Due to
these receptors’ wide-ranging role in so many diseases, it is not surprising that almost half of all
FDA-approved drugs target GPCRs for their biological effects. The ligands in cells bind to the
GPCR extracellularly to induce a conformation change that activates an intracellular G-protein.
This activated G-protein is then capable of signaling through two mechanisms of action, as seen
in Figure 2. The first mechanism involves adenylyl cyclase, which produces cAMP as a secondary
messenger. The second involves phospholipase C, which is capable of enzymatically hydrolyzing
phosphatidylinositol 4,5 bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1,4,5
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triphosphate (IP3). IP3 then binds to the IP3 receptor on the ER membrane, causing calcium
stores from the ER to empty into the cytoplasm and act as a second messenger to carry out the
biological functions [31]. Activation of phospholipase C via G-protein signaling has also been
shown to increase intracellular calcium by store depletion and the subsequent activation of
TRPC channels [32,33].
Mutations in GPCRs, such as point mutations, overexpression, and silencing, have
contributed to either cell death or tumor initiation and EMT. One of the more common
alterations discovered after analyzing an mRNA database was GPCR overexpression, coupled
with a more frequent mutation rate, which has been found across 20 different cancers,
including 45 subtypes, as compared to non-cancerous tissues [34]. These overexpressed GPCRs
encompassed all classes, including A, B, C, adhesion, and orphan GPCRs. Since GPCRs can signal
to initiate biological processes, such as proliferation and migration, a significant increase in
receptors would allow for greater signaling output in these pathways. One example of this
phenomenon is found in the family of GPCRs known as chemokine receptors. One role
chemokines play in tumorigenesis and EMT is the recruitment of tumor-associated
macrophages (TAMs), which leads to the release of MMPs [35]. An illustration of this is shown
in Figure 2. These MMPs enhance motility by breaking down proteins in the basement
membrane and extracellular matrix, to allow cells to metastasize away from the primary tumor.
Recently, several types of the GPCR, protease-activated receptor (PAR), have been found to be
upregulated in cancer [36]. Interestingly, the overexpression of PAR was found to induce EMT
via TGF-β signaling, leading to the loss of cell polarity [37]. Point mutations in the binding
pocket of GPCRs can also be crucial in the viability of cancer cells. The mutations can alter
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ligand–receptor affinity along with ligand selectivity, which can change the entire signaling
pathway through its respective receptor [38]. After analyzing one specific GPCR known as
adenosine A2B receptor, a previous study found altered agonist efficacy and potency, with 15
different point mutations [39]. While some of these mutations increased the agonist effect,
others reduced or completely eliminated receptor activation, demonstrating how minute
changes in the protein sequence can completely transform this GPCR’s capabilities. Recent
work has also substantiated GPCRs’ role in the upregulation of EMT transcription factors, such
as ZEB, Snail, and Twist, which are involved in numerous transitions, including cell polarity,
cytoskeleton remodeling, migration, and invasion [36,40]. It has been challenging to delineate
the actual function and various ligands of all GPCRs, due to their extensive crosstalk with the
proteins and pathways that perform the vast majority of cellular functions.

Integrins

Integrins are transmembrane adhesion receptors that have a primary role in cell–cell
and cell–ECM binding, with a secondary role in signaling as well. They are essential for
physiological development and are crucial in each step of the development and progression of
cancer [41]. The first step in EMT occurs when cell–cell connections are lost and the ECM gains
motility. In order for these cells to avoid apoptosis via a process known as anoikis, they rewire
their genetic makeup in order to survive on their own, despite losing these connections [42].
There is evidence to suggest that the crosstalk between GPCRs, calcium channels, and integrins,
ultimately leading towards EMT, makes this possible (Figure 3). Research studies have shown
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that certain calcium-sensing G-proteins form signaling complexes with integrins to aid in cell
differentiation and movement in cancers. For example, a GPCR with augmented expression
from increased extracellular calcium, known as CXCR4, activates a GTPase, known as Rap1,
which modulates integrin inside-out signaling by binding talin to β-integrin. This enhances cell–
ECM connections, assisting in cellular migration and cytoskeleton rearrangement [43]. One
study found that the overexpression of Orai1 was linked to survival of breast cancer cells, a
finding that was associated with increased collagen–integrin interactions [44].
In addition, recent studies have found that calcium directly modulates integrin activity.
Integrin subunits are formed in the ER and then released into the cytoplasm, and the proper
folding of these proteins requires the presence of divalent calcium ions [45]. Additionally, the
alpha and beta subunits of integrins cannot localize or activate the conformation in the plasma
membrane without the calcium ions. Calcium bound to integrins during transport ensures
inactivation until the integrins are membrane bound and the calcium is displaced by additional
cations, such as magnesium and manganese, to form an active conformation. Calcium allows
the two subunits to dimerize in the ER and translocate to the plasma membrane via
endocytosed vesicles for proper functionality [45]. It was also found that manganese and
magnesium work in conjunction with calcium to help bridge the integrin–ECM connection,
allowing for integrin signaling and cell adhesion [46]. One study found that calcium located at
the filipodia of cells was able to modulate the signal transduction process in integrins that were
used in migration and invasion for the purpose of tumorigenesis [47]. Whether used in
complexes and signaling or directly in cells, calcium has been shown to interact with integrins
that regulate normal biological and pathological progressions.
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Calcium in Immune Evasion and Drug Resistance
The most proliferative and aggressive cancer cells possess essential characteristics that
enable them to evade immune surveillance [48,49,50,51,52] and become resistant to drug
treatment [53,54,55,56,57,58,59,60,61,62]. These characteristics also enable proliferative and
aggressive cancer cells to undergo EMT. Cancer cells often contain mutated antigens on the cell
surface that are typically marked as non-self by locally activated T cells. Tumor cells with similar
antigen presentation are, therefore, disposed of via T-cell infiltration and elimination. The
binding of the antigen receptor on the tumor cell to the antigen receptor on the lymphocyte
activates phospholipase C, capable of generating IP3 and inducing SOCE. This store-operated
calcium is used as a second messenger in the lymphocyte to transcriptionally activate NFAT.
The lymphocyte is then able to release the calcium-dependent perforin, which disrupts the
cancer cells’ membranes, leading to cell death [63]. This process can be initiated in immune
cells and blocked in cancer cells by the use of calcium signaling. Cancer cells have manipulated
calcium signaling, so that the immune system is no longer able to recognize and dispose of
these abnormal cells. The tumor microenvironment plays an essential role in this process, in
conjunction with the cancer cells themselves. As previously mentioned in Figure 2, cancer cells
are capable of recruiting TAMs through calcium-induced transcriptional regulations to aid in
cancer progression. For example, one study found that TAMs colocalized from a wide array of
breast carcinomas were involved in the enhancement of tumor progression by producing a
chemokine known as CCL18. TAMs located in the breast tumor microenvironment that release

32

CCL18 were able to activate a GPCR known as NIR1. This triggered integrin clustering and ECM
remodeling in tumor cells, which were associated with increased calcium signaling through
IP3 generation, metastasis in multiple sites outside the primary tumor in patients, and poor
survival [64]. In addition, by analyzing calcium-dependent and perforin-dependent cytotoxicity
in multiple tumor types [65], experiments have shown that the overexpression of Orai1 and
excess calcium signaling in cancer cause a reduction in the cytotoxic effect of natural killer cells
and the ability of cytotoxic T-lymphocytes to eliminate the cancer. In contrast, the inhibition of
Orai1 via siRNA and reduced extracellular calcium decrease cancer cell proliferation and
enhance the cytotoxicity of cytotoxic T-lymphocytes and natural killer cells to tumors [65].
While intrinsic factors of tumor cells interacting with the tumor microenvironment can help
cells avoid immune detection, extrinsic factors outside these cells can affect cellular processes
that lead to drug resistance as well.
Sources of extracellular stress, such as hypoxia, lack of nutrients, and drug pressure,
contribute to the induction of EMT by forcing cells to a crossroad of either adapting or dying.
Calcium signaling is an important contributor to this process. Small calcium deposits in the
tumor microenvironment, known as microcalcifications, have recently been studied as potential
links to EMT, and may be a source or product of this increased calcium. One study of prostate
cancer found a correlation between microcalcifications and increased bone metastasis [66].
Another study found a similar correlation of microcalcifications and EMT markers, such as CD44
and vimentin, in breast cancer, which could predict a poor prognosis in patients [67].
Intracellular calcium fluctuations have been shown to play a role in epigenetic programs and
transcriptional regulation to allow cells to survive in the most extreme cases. For example,
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sustained calcium entry by means of SOCE has been shown to activate the NFAT/CREB pathway,
which induces transcriptional modifications in cells for the progression of tumorigenesis [68]. In
contrast, the inhibition of calcium flux causes cancer cells to have increased sensitivity to drug
treatment [69]. Further research is still needed to assess whether inhibiting calcium flux results
in better patient outcomes. On the cell surface, channels and pumps undergo mutations to
improve survival in the face of drug treatments as well. For example, Stim1 was found to work
in conjunction with Orai1 to mediate TGF-β, which induces a key transcriptional factor of EMT,
called snai1, that corresponds with drug resistance [70]. In contrast, efflux pumps play a vital
role in cell survival. One study illustrated the role of sorcin (SOluble Resistance-related Calciumbinding ProteIN) overexpression in cancer, which modulates the co-overexpression of ABC
(adenosine triphosphate-binding cassette) transporters serving as a survival mechanism by
efficiently effluxing drugs out of the cells, in addition to sorcin’s ability to induce EMT [71].
Currently, sorcin is viewed as an oncogene that could be central to multidrug resistance in
clinical settings and a viable target for new drug discovery [71]. Furthermore, persister cells in
cancer are a common cause of treatment failure and patient relapse. Persister cells make up a
very small proportion of malignant cells and have adapted to survive extremely lethal doses of
drug treatment [72]. They can also remain in a state of dormancy for extended periods of time,
which, in conjunction with a decelerated cell cycle, enables them to acquire mutations that
allow for cellular progression [73]. Research has substantiated a consistent trait of these
persister cells as having increased calcium signaling in parallel with cytoskeleton remodeling
[74]. Understanding the vast array of mechanisms of resistance remains crucial for future drug
discovery and optimizing combination therapy.
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Combination Therapy
The heterogeneity of tumors within their microenvironment has proven to be one of the
biggest obstacles in treatment. Tumors create diversity through cellular differentiation to
obtain a more sustainable environment and prevent their eradication [75,76,77,78,79,80,81].
Evasion of immune surveillance, angiogenesis, ECM remodeling, blockage of apoptosis, and
multidrug resistance are all ways in which tumors are able to proliferate and explain why they
cannot be captured by a single cellular phenotype. Calcium remains at the center of all of these
malignant processes (Figure 1). In order to optimize patient treatment, it is often beneficial to
use combination therapy to combat the heterogeneity of the tumor microenvironment.
Combination therapy is a practice used for almost all cancers and subtypes. Additional details of
how more well-studied cancers, including breast, lung, and colon cancer, respond to
combination treatment are presented below.
Breast Cancer is one of the most common types of cancer and kills more women than
any other cancer worldwide [82]. It has been characterized by its many mutations, including
human epidermal growth factor 2 (HER2), breast cancer genes 1 and 2 (BRCA1/2), and
phosphatase and tensin homolog (PTEN) [83]. Within these mutational subtypes, studies have
found alterations of calcium channels and pumps that play a part in the proliferation of breast
cancer cells, such as changes in expression and localization, and which allow for sustained
calcium signaling [84]. Targeting unique cancer characteristics, such as driver mutations and
calcium fluctuations, may be necessary for optimal treatment. Further evidence of this,
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involving a calcium channel known as TRPV6, which is found to be overexpressed in breast
cancer, along with many other cancers, has been found in clinical settings. Clinical trials are
ongoing with a novel TRPV6 inhibitor, in conjunction with standard-of-care therapy, for multiple
subtypes of breast cancer, since some current treatments, such as tamoxifen, have been shown
to negatively affect the TRPV6 channel as well [85]. Many of the current standard-of-care
chemotherapy agents also target calcium signaling for the treatment of breast cancer. Cisplatin
and tamoxifen act by causing an overwhelming influx of calcium and ER store depletion that
leads to cell death, while doxorubicin induces sustained calcium flux, which activates the
proapoptotic BIM pathway and causes mitochondrial calcium overload [86].
Lung Cancer is heavily burdened by mutational drivers that make targeted therapy a
promising avenue for drug development and impactful in terms of patient outcomes. Some of
the more common mutations include epidermal growth factor receptor (EGFR), KRAS, and ALK.
EGFR inhibitors remain the most well-developed targeted inhibitors, with strategies to target
the most common resistance mutation, T790M, for this disease. Epidermal growth factor (EGF),
the ligand for EGFR, was found to play a role in the calcium oscillations essential for EMT [87].
The evidence suggests that the blockage of cells from extracellular calcium via a calcium
chelator known as EGTA increases the efficacy of EGFR inhibitors such as afatinib [74].
Immunotherapies are also on the rise in cancer treatment. One study found that blocking
calcium channels can suppress the transcription of programmed death-ligand 1 (PD-L1) and
enhance natural killers cells’ ability to eliminate the cancer [88]. Chemotherapies that target
calcium signaling, similar to those used against breast cancer, such as cisplatin and doxorubicin,
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were found to be synergistic in combination with EGFR inhibitors (gefitinib and erlotinib) and to
prolong patient survival in the clinic [89].
Colon Cancer is the third most common cause of cancer-related death. Little is known
about the causes, but the most prominent driver mutations include adenomatous polyposis coli
(APC), BRAF, and KRAS [90]. SERCA channels are often targeted to deplete ER calcium stores.
One SERCA channel blocker used in combination with standard-of-care drugs for colon cancer is
called thapsigargin [91]. Stim1 and Orai1 inhibitors have also been used to increase patient
survival rates [91]. In addition, one standard-of-care drug for colon cancer, known as 5
Fluorouracil (5-FU), acts by modulating calcium itself. 5-FU was found to signal through a
calcium-dependent pathway in order to induce apoptosis [92].
By incorporating the role of calcium signaling in the development of new drugs,
therapies can evolve to optimize cancer treatment. This has been shown in the treatment of
other cancers, such as prostate, pancreatic, and glioblastoma. As with lung cancer treatment,
cisplatin and paclitaxel alter calcium homeostasis and remain an effective first-line treatment
for prostate cancer that has an overexpression of TRPV channels [93,94]. Pancreatic cancer is
similar to colon cancer, with the infamous KRAS mutation and the overexpression of Orai1. An
additional similarity between the two malignancies is the use of the calcium-induced apoptosis
treatment of 5-FU [95]. Even glioblastoma, one of the most lethal cancers, has started to be
treated with calcium-altering therapies. T-Type calcium channel blockers, combined with
temozolomide (TMZ), are in the early stages of clinical trials for use in the treatment of highgrade gliomas [96,97]. A comprehensive table, containing calcium alterations across multiple
cancers and calcium pathway-targeting therapies, is shown in Table 1. Combination therapy has
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become especially important with the increasing knowledge of EMT and multidrug-resistant
mechanisms. While some standard-of-care drugs directly target calcium pathways, targeting
multiple broad mutations of the heterogenous population within the tumor microenvironment
may effectively reduce drug resistance and improve long-term patient outcomes.

Conclusion

Cancer constantly evolves, with mutational burdens that are continually being explored.
Therefore, understanding commonalities that lead to the development of a more malignant
EMT phenotype is essential for drug discovery and the expansion of combination therapies. A
plethora of evidence has substantiated the fact that calcium plays a critical role in the EMT
process, leading to immune evasion and drug resistance. Calcium modulates cellular functions
by inducing alterations in calcium channels; interacting with receptors; and remodeling the
ECM signaling pathways, transcription, and epigenetics. This allows normal cells to transition
into cancer cells. Insights into specific changes at a transcriptional and protein level will aid in
the construction of new targeted therapies to optimize the eradication of the heterogenous
tumor population. Since the EMT is a transient process, the reversal of a malignant phenotype
or the blockage of its progression would also be a viable option for improving patient
outcomes. Calcium signaling and its crosstalk with a multitude of additional signaling pathways
can obscure correlative data as causative evidence. As a result, further research is needed to
improve knowledge on delineating calcium’s many roles in the EMT process and cancer
progression, to help those faced with this deadly disease.
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Table 1: Calcium changes by cancer type as a result of therapies targeting calcium pathways. ↑
(increase in expression)
Cancer Type
Lung

Breast

Colon

Prostate
Pancreatic
Glioblastoma

Mutational
Drivers
EGFR
KRAS
ALK
HER2
BRCA1/2
PTEN
APC
KRAS
BRAF
FOXA1
TP53
PTEN
KRAS
TP53
LOH Loss

Calcium
Alterations
↑Orai1
↑TRPC1,3,4,6

Calcium Altering Therapies
Cisplatin
Doxorubicin
Afitinib
Cisplatin
Tamoxifen
TRPV6 Inhibitor
Stim1/Orai1 Inhibitors
Thapsigargin
5-FU

↑TRPV6
↑Stim1/Orai1
↑SERCA2
↑IP3
↑TRPV1
↑TRPV2
↑TRPM7
↑Orai1
↑TRPV1
↑TRPV2

Paclitaxel
Cisplatin
5-FU

Reference

[22,74,87]

[83,85,86]

[90–92]

[93,94]

[95,98]
T-Type Calcium Channel Blocker Combined
with TMZ
[96,97]
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Figure Legends
Figure 1. Role of calcium in epithelial-to-mesenchymal transition (EMT). Tumor associated
macrophages (TAMs); Extracellular matrix (ECM); G-protein coupled receptor (GPCR); T-cell
receptor (TCR)
Figure 2. GPCR signaling induces EMT. This schematic illustrates the activation of a GPCR
signaling pathway when bound to a ligand such as a chemokine. Both signal transduction
pathways have the ability to induce EMT at a transcriptional level by activating genes such as
Snail, Twist, and ZEB. GPCR signals that transcriptionally activate EMT genes are capable of
recruiting TAMs to the tumor microenvironment. TAMs produce MMPs that allow these cells to
invade and metastasize in the EMT process. Diacylglycerol (DAG); Inositol trisphosphate (IP3);
Cyclic adenosine monophosphate (cAMP)
Figure 3. Calcium alterations causative of EMT. This schematic illustrates the role of calcium
signaling, which is required for progression from a normal epithelial cell to an EMT phenotype
associated with metastatic cancer cells, by showing (1) The starting point of a healthy epithelial
cell containing all tight junction proteins and physiological levels of GPCRs and calcium
channels. (2) Gradual reduction in junction proteins and increased calcium channel production.
(3) Gradual increase in mesenchymal proteins, such as Vimentin and N-Cadherin, and GPCRs
acquiring mutations. (4) ECM dissociation through integrins. (5) Increased motility. (6) Invasion
of a cancer cell into bloodstream, to metastasize away from primary tumor. Junctional adhesion
molecule (JAM); Zinc finger E-box-binding-homeobox (ZEB)
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Simple Summary
MTI-101 is a first-in-class novel cyclic peptide shown to have anti-tumor activity in both
multiple myeloma and castrate-resistant prostate in vivo cancer models. These data suggest the
potential for a broad spectrum of anti-cancer activity for this class of compounds. To further
delineate determinants of sensitivity and resistance that were not dependent on oncogenic
drivers, two isogenic drug-resistant cell lines were generated with chronic exposure to MTI-101
in a non-small cell lung cancer (NSCLC) PC-9 (EGFR driven) and a small cell lung cancer (SCLC)
H446 (PTEN deleted and c-MYC amplified). Our data indicate that the chronic exposure of MTI101 selects for a stable mesenchymal-to-epithelial (MET) genotype and phenotype in both PC-9
and H446 lung cancer cell lines.

Abstract
MTI-101 is a first-in-class cyclic peptide that kills cells via calcium overload in a caspaseindependent manner. Understanding biomarkers of response is critical for positioning a novel
therapeutic toward clinical development. Isogenic MTI-101-acquired drug-resistant lung cancer
cell line systems (PC-9 and H446) coupled with differential RNA-SEQ analysis indicated that
downregulated genes were enriched in the hallmark gene set for epithelial-to-mesenchymal
transition (EMT) in both MTI-101-acquired resistant cell lines. The RNA-SEQ results were
consistent with changes in the phenotype, including a decreased invasion in Matrigel and
expression changes in EMT markers (E-cadherin, vimentin and Twist) at the protein level.
Furthermore, in the EGFR-driven PC-9 cell line, selection for resistance towards MTI-101
resulted in collateral sensitivity toward EGFR inhibitors. MTI-101 treatment showed synergistic
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activity with the standard of care agents erlotinib, osimertinib and cisplatin when used in
combination in PC-9 and H446 cells, respectively. Finally, in vivo data indicate that MTI-101
treatment selects for increased E-cadherin and decreased vimentin in H446, along with a
decreased incident of bone metastasis in the PC-9 in vivo model. Together, these data indicate
that chronic MTI-101 treatment can lead to a change in cell state that could potentially be
leveraged therapeutically to reduce metastatic disease.

Introduction
Lung cancer is the deadliest of all cancers and accounts for more deaths each year than
breast, prostate and colon cancer combined [1]. Upon diagnosis, lung cancer can be
categorized into two subtypes: small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). Almost all SCLC patients are current or former tobacco smokers, and cases of SCLC
typically have very aggressive tumors grouped with a poor five-year survival rate below seven
percent [2]. There are few treatment options for SCLC patients because many of the identified
molecular drivers are not currently druggable, along with the presence of considerable tumor
heterogeneity, which likely contributes to the rapid emergence of drug resistant disease. The
emergence of resistance and metastatic disease contributes to the 5-year survival rate of SCLC
patients at a dismal 7 %. In contrast, NSCLC patients include smokers and non-smokers. In fact,
10-15 % of all NSCLC newly diagnosed patients have never smoked[3]. Many therapeutically
actionable mutational drivers have been identified in this class of lung cancer such as EGFR and
ALK mutations that allow for targeted therapies for these subsets of lung cancer patients.
Despite advances in targeted therapeutics, metastatic NSCLC remains a deadly disease due to
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the rapid emergence of drug resistance. Recent data indicate that one way to combat drug
resistance is to design therapeutic strategies that keep a drug sensitive population available for
further treatment. Thus, considering compounds that have non-overlapping drug-resistant
profiles and alternating the schedule as single agents may lead to improved patient outcomes
by delaying the emergence of an aggressive drug-resistant phenotype [4].
MTI-101 is a first-in-class novel therapeutic agent that was originally derived from a
linear peptide known as HYD-1, found in a high throughput screen that utilized inhibition of cell
adhesion as a phenotypic endpoint[5]. It was later found to induce cell death in cancer cells by
altering calcium homeostasis in a caspase-independent manner[6]. Experimental evidence
indicates that MTI-101 selectively targets cancer cells via activation of a TRPC complex and
calcium entry, leading to cell death [7-8]. MTI-101 has shown strong activity in relapsed
multiple myeloma primary patient specimens tested ex-vivo and castrate-resistant prostate in
vivo models by reducing tumor volume and increasing survival with little observed toxicity at
the efficacious doses used for in vivo studies [7,9]. Interestingly, resistance to HYD-1 in
myeloma cell lines resulted in a compromised cell adhesion-mediated resistant phenotype,
suggesting that resistance emerged at an overall cost to the cell, related to cell adhesion[10].
We hypothesized that this cyclized peptide known as MTI-101 may be an attractive therapeutic
agent for metastatic lung cancer, as calcium signaling pathways are critical for metastasis[11].
Identification of phenotypic traits and changes in states due to genotypic changes that occur
with acquisition of resistance to MTI-101 will enhance the understanding of how to clinically
position this first-in-class molecule.

61

The primary site of a tumor will eventually be limited by resources which places an
initial selection pressure to favor cells which are capable of invading the surrounding tissue or
relocate to additional regions in the body to obtain the necessary nutrients for the survival of
rapidly dividing cells. This cellular rearrangement called epithelial to mesenchymal transition
(EMT) is found to take place in normal cells for task such as development and wound healing,
but cancer cells can undergo these changes in response to stress stimuli[12-14]. This transition
allows for epithelial like tumor cells to alter gene expression such as decreasing epithelial
proteins, including E-cadherin, claudin, and occludin while increasing mesenchymal proteins
such as Vimentin (VIM), N-cadherin, and fibronectin (FN1), allowing them to survive after losing
contact from adjacent cells and the basement membrane[15]. EMT cells can undergo
cytoskeleton rearrangement to become more motile and also produce proteins such as matrix
metalloproteases (MMPs) that allow them to invade into new tissues and metastasize[16-17].
Clinically, malignant cells displaying an EMT phenotype after drug treatment correspond with a
poor prognosis that leads to decreased relapse time and increased metastatic tumor sites[1820]. This transition is transient, and cells can also change to a more epithelial like phenotype
moving toward MET[21]. Patients that are treated with current standard of care therapies for
lung cancer often experience relapse that give rise to drug resistant tumors that have
undergone EMT[20]. Recent studies have shed light on EMT as a spectrum of cell states
compared to a binary process[22]. Early models supported the claim of the existence of hybrid
EMT models by developing mathematical equations to describe a unique model of the
microRNA-based coupled chimeric modules that utilize ZEB and Snail mutual inhibition
feedback circuits[23]. This phenomenon was further explained by Snail microRNA serving as a

62

reversible switch to initiate EMT, while ZEB microRNA acts as an irreversible switch to establish
the mesenchymal state with the interplay of TGF-b signaling[24]. More recent studies in vivo
have shown that due to the heterogeneity of tumor populations, there are six distinct EMT
subpopulations that exist based on cell surface markers that differentiate cellular plasticity,
invasiveness and metastatic potential[25]. Due to the unique mechanism of action of MTI-101,
we sought to further understand the emerging drug resistant phenotype using in vitro and in
vivo models. Emergence of resistant cell lines were analyzed in comparison to the wildtype
(WT) to determine the genotype and corresponding phenotype the drug is selecting for in lung
cancer. These data may allow for identification of new actionable vulnerabilities that emerge
with chronic selection pressure of MTI-101 treatment that may inform rational therapeutic
strategies to be further validated in pre-clinical lung cancer models prior to the development of
clinical strategies.

Materials and Methods
Cell Culture/Reagents- PC-9 (Sigma #90071810) H446 (ATCC #HTB-171) and HCC4006 (ATCC
#CRL-2871) lung cancer cell lines were used as parental cell lines. MTI-101 resistant cell lines
PC-9R and H446-R were developed with chronic exposure to MTI-101 over a 6-month period.
All cell lines were maintained in RPMI-1640 L-Glutamine with 10% Fetal Bovine Serum, and 1%
penicillin/Streptomycin. Resistant cell lines were maintained with a constant level of MTI-101
in culture media (60µM for PC-9R and 40 µM for H446-R). All cell lines were tested for
mycoplasma every six months, and STTR analysis was performed on a yearly basis.
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MTT Assays- PC-9 cells were seeded at 10,000 cells/180 µL media and H446 was seeded at
20,000 cells/180 µL media in each well of a 96 well plate. The following day, 20 µL of varying
drug concentrations of MTI-101 dissolved in sterile water was added to each treatment group
with 20 µL of sterile water added to the controls. 24 hours after the introduction of MTI-101,
50 µL of MTT dye was added to each well and incubated for one hour. Following incubation,
the media/dye was aspirated off, and the cells were resuspended in 200 µL of DMSO and the
absorbance of each well was read on a plate reader at 570 nm. A Log10 (Dose) curve was
generated using GraphPad to calculate the IC50 values of each cell line.
Western Blots- All Cells were lysed in buffer composed of 50 mm Tris (pH 7.4), 5 mm EDTA, 150
mm NaCl, and 0.5% Triton X-100 containing 1 μg/mL leupeptin and aprotinin and 1
mm phenylmethyl sulfonyl fluoride. The protein content of cell lysates was quantified by using
the Pierce BCA protein assay kit, and equal amounts of the total protein were dissolved in
Laemmli SDS-PAGE sample buffer prior to separation by 15% SDS-PAGE. Proteins were
transferred to polyvinylidene difluoride membrane (Bio-Rad), and Western blot analysis was
performed by using standard techniques with enhanced chemiluminescence detection
(Roche/Boehringer Mannheim, Indianapolis, IN). The following antibodies were used in this
experiment: E-cadherin, Vimentin, B-catenin, TWIST1, B-actin (Cell Signaling, Cat #-3195T,
5741T, 8480T, 46702, 4967S) and TWIST2 (ThermoFisher 66544-1-IG).
Invasion Assay- PC-9 cells were seeded at 25,000 cells/ mL media and H446 cells were seeded
at 40,000 cells/ mL. 100 µL was dispensed in each well of a 96 well round bottom plate.
Spheroids were allowed to form for 48 hours. Then, 70 µL media was slowly aspirated off and
the plate was placed on ice for 5 minutes. Next, 70 µL of Matrigel was slowly added on top of
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each spheroid and placed in the incubator to allow gel solidification for 1 hour. Following
incubation, each well was topped with 100 µL media to prevent the gel from drying out and the
plate was placed on the Biotek Lionheart imager to track invasion over a 48-hour period. The
image montage was stitched and the most in focus z-parameter was selected for each time
point. Invasion distance was quantified by creating a primary mask on the original spheroid at
Time 0 and tracked over time divided by the Time 0 mask for the duration of the invasion assay.
Anoikis Assay- Apoptosis assays for anoikis were performed by assaying Annexin v/pI staining.
500,000 cells (50,000 cells/mL) were placed in 100 mm ultralow attachment dish (0.5% methyl
cellulose; Sigma-Aldrich) for 24 hours. The apoptotic cells were determined using propidium
iodide (pI, 2µg/ml; Thermo Fisher) and Annexinv V-APC (1 µg/ml; BD Biosystems) using a
FACScan flow cytometer (BD biosystems).
RNA Extraction- Quadruplicates of RNA were extracted from each WT and resistant lines of PC9 and H446 using RNeasy Plus Mini Kit (Qiagen, cat#74104). 2-3 million cells were isolated in a
dry pellet and resuspended and RNA was initially extracted using Trizol, and then further
purified using the Qiagen RNeasy Mini Protocol and RNA was stored at -80 degrees. The same
RNA isolation procedure was performed for the PC-9 4, 5, and 6 months removed from drug
(RFD).
RNA-Seq Data Analysis- RNA-Seq libraries were sequenced at Marshall University Genomics
Core with Illumina NextSeq 2000. Pair-end RNA-SEQ short reads were aligned to the whole
human reference genome (hg38) by subread v2.0.1[26]. The total number of reads aligned to
transcripts at gene level were summarized by featurecounts from Rsubread v2.2.0[27] with
built-in RefSeq gene annotation. Gene expression level was quantified by RPKM (reads per
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kilobase of exon model per million mapped)[28]. We used edgeR v3.30.3[29] to define
differentially expressed (DE) genes with the following criteria: p-value < 0.05, fold change >1.5,
and CPM (count per million; log2)> 0. To determine the relationship between expression
changes of PC-9 and H446 to their MTI-101 resistant counter parts, we employed Gene Set
Enrichment Analysis through GSEA v4.0.2. We created three “rnk” files based on fold change of
expression (treatment vs baseline) for the following comparisons: PC-9R vs PC-9, H446-R vs
H446 and PC-9 RFD vs PC-9; a “rnk” file consist of one column for gene symbol and another for
fold-change of expression. The rnk file was then supplied as input to GSEA to determine the
significance of a preferential expression for selected gene sets from MSigDB in treatment
condition over the baseline, or vice versa.
Transfections- PC-9 and H446 cells were transfected with a tomato red/LUC vector (pcDBA3.1
(+)/Luv2=tdT, Addgene #32904) [30] by electroporation using an Amexa nucleofection kit and
Amexa nucleofector instrument per manufacture’s recommendation.
In Vivo Animal Studies- (H446 tomato red/LUC) A single treatment MTI-101 study was
conducted in SCID/BEIGE mice to understand the single agent effect of MTI-101 in lung cancer.
The mice (6-8 weeks old Male/Female) were injected with 5 million H446 cells (transfected with
tomato red/LUC) via tail vein, allowed to engraft for four weeks and imaged on IVIS for tumor
location and progression. Fourteen (M/F) mice were separated into two groups dividing tumor
burden, location of tumor, and gender evenly. One group was treated with 20mM histidine
(vehicle control) while the other was treated with 10 mg/kg MTI-101 via IP injection three times
a week for the duration of the study (200 days). Once mice met study endpoints per ACUC
protocol, mice were euthanized, and kidneys were collected for further analysis. In the H446
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model, cells engrafted consistently in the kidneys and thus this organ was processed for further
analysis. Vimentin, E-cadherin, and b-catenin stains were completed on slices of these kidneys
of both groups. (PC-9 tomato red/LUC) A similar study was also conducted using the EGFR
Driven NSCLC PC-9. The mice (6-8 weeks old M/F) were injected with 2 million PC-9 cells
(transfected with tomato red/LUC) via tail vein, allowed to engraft for three weeks and imaged
on IVIS for tumor location and progression. Twenty-one mice were separated into two groups
dividing tumor burden, location of tumor and gender evenly. One group was treated with
20mM histidine (vehicle control) while the other was treated with 10 mg/kg MTI-101 via IP
injection beginning 3 weeks post tumor injection for 12 weeks. Once mice met study endpoints
per IACUC guidelines, they were euthanized, and lungs were collected for further analysis of
MET markers including Vimentin (Ventana #790-2917) , E-Cadherin (Ventana #790-4497), and
B-catenin (Cell Marque #224M-14). Lung tissue sections were also stained with H&E to confirm
presence of tumor, and IHC was used to detect markers of MET. For IHC studies, tissues
obtained from 6 mice from control and 6 mice from the MTI-101 treated cohort were analyzed.
Fiji software was used to analyze mean intensity based on tumor area.
All in-vivo study designs were approved by the West Virginia University ACUC board.

Results
Development of Isogenic MTI-101 Resistant Lung Cancer Cell Lines
The development of isogenic-acquired drug-resistant cell lines is one strategy to identify
determinants of sensitivity and resistance [31,32] to novel therapeutics. The isogenic cell lines
allowed for paired analysis using RNA-SEQ to match the genotype to the emerging phenotype.
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PC-9 and H446 WT cell lines were initially treated with a low dose (10 μM) of MTI-101. The
surviving or resistant cells were treated each subsequent time with 10 μM MTI-101 until they
were able to proliferate at approximately the same rate as the parental WT cell line. The dose
was then increased by 10 μM increments until a stable drug-resistant variant emerged. H446
was able to reach a 40 μM resistant level whereas PC- 9 was stable up to a 60 μM resistant
level. Interestingly, increasing the drug concentration beyond these doses was not achieved, as
cultures did not sustain growth with an increased selection pressure. The stable variants were
then compared to the respective WT cell line using an MTT analysis to assess resistant levels.
The IC50 value shown is an average (n = 3 independent experiments) using the log dose of MTI101 and viability compared to the control with non-linear regression on GraphPad. H446 and
H446-R had, respectively, an IC50 value of 16.71 ± 3.97 and 34.51 ± 10.86 μM (Figure 1A). PC-9
and PC-9R had an IC50 value of 37.47 ± 4.33 and 82.11 ± 12.37 μM (Figure 1B). It was surprising
to us that we could not select for higher levels of resistance, suggesting that a robust drug
resistance phenotype may emerge at a high cost to overall fitness. In order to determine
whether MTI-101 demonstrates specificity toward lung cancer cells, a healthy bronchial
epithelial cell line known as BEAS-2B was also treated with the same range of doses of MTI-101
to determine its sensitivity. The IC50 value for BEAS-2B with treatment of MTI-101 was found to
be 116.07 ± 29.05 μM. Together, these data indicate that lung cancer cells demonstrate an
increased sensitivity compared to normal epithelial lung cells toward treatment with MTI-101.
During the development of the two isogenic MTI-101-resistant lung cancer cell lines,
morphological images were taken using bright field microscopy (20X), comparing each to their
respective WT cell lines (Figure 1C,D). The resistant cell lines appeared to be more clumped and
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adherent to the culture dish than the WT that formed an even monolayer in vitro, suggesting
increased cell–cell connections with resistance. This observation is suggestive of resistant cells
converting to a more epithelial phenotype compared to the parental line. In parallel with
morphological changes, resistant cells were also found to be significantly more sensitive to
anoikis-induced apoptosis than their WT counterpart (Figure 1E,F).

Bioinformatic Analysis Discovers Enrichment of MET in Resistant Cell Lines
We applied RNA-seq analysis to determine differences in transcriptomes among PC-9
and H446 lung cancer cell lines and their MTI-101 resistant variants, PC-9R and H446-R,
respectively. To determine the stability of changes in the transcriptome, the PC-9R line was
removed from MTI-101 drug pressure and RNA was collected at four, five and six months post
drug removal. PCA analysis based on gene expression revealed that replicates from the same
cell lines were clustered together, confirming the high reproducibility of the data (Figure 2A).
The x-axis from the PCA plot depicts the cell type difference, and the y-axis demonstrates the
expression difference between parental and MTI-101-resistant lines. The PC-9 RFD samples
were closer to PC-9R than PC-9, indicating that removing the drug pressure for six months failed
to convert the transcriptome of the resistant line back to its parental line. Gene set enrichment
analysis was performed to determine pathways differentially expressed between WT and
resistant cells. The results revealed that EMT is the most downregulated hallmark gene set in
the MTI-101 resistance lines when compared to their parental lines (Figure 2B,C). Consistent
with the PCA analysis, PC-9 RFD compared to PC-9 was also downregulated for the EMT gene
set (Figure 2D), illustrating its similarity with PC-9R and the stability of the transcriptome
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signature after relieving drug pressure. A Venn diagram analysis was conducted to compare all
the differentially expressed genes between resistant cell lines and the WT lines (Figure 2E). It
identified 329 genes commonly shared by all. Genes related to EMT in PC-9 were individually
analyzed, including SPARC, vimentin, fibronectin, TWIST2 and PLOD2 (Figure 2F). Similar
significant results were found in the negative expression of these EMT genes in the H446 cell
line as well (Supplemental Figure S1). In addition, these same genes were analyzed by relating
their expression to the patient overall survival through the lung cancer Kaplan–Meier KM
Plotter [33]. A low expression of TWIST1, fibronectin and PLOD2 predicted a significant
increased patient survival (Figure 2G). In contrast, no changes in survival were observed based
on the expression of SPARC or TWIST2 and the surprisingly low VIM expression as a single gene
correlated with poor outcomes. Interestingly, EMT was negatively enriched in both resistant
cell lines despite the vast differences in starting transcriptomes between the parental PC-9 and
H446 with the sole selection pressure of MTI-101 treatment.

Emergence of Resistance to MTI-101 Selects for a Stable Phenotype Associated with
Diminished Invasive Capacity and Increased Expression of Epithelial Markers
Based on differential gene expression profiling, one of the only transcription factors
shown to induce EMT that was differentially expressed in both cells lines was TWIST. Comparing
parental to resistant lines, TWIST1 was significantly decreased in the H446-resistant variant
(Figure 3A,B). In PC-9 cells, the basal level of TWIST1 is low and was further diminished in the
resistant line (albeit the quantification of three blots did not show significance, p > 0.05 T-Test).
In contrast, TWIST2 was significantly decreased in the PC-9 resistant variant (Figure 3C,D). The
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original Western blots for individual runs are contained in the Supplemental Figure S2-S4 for
TWIST1 and Supplemental Figure S5-S7 for TWIST2. The TWIST2 expression in H446-R did
appear to trend towards an increased expression compared to H446, but was not found to be
significant (p > 0.05, T-test n = 3). It is important to note that even though this difference is only
two-fold, it could be compensating for a decreased TWIST1 expression in H446. For
comparison, there was a ten-fold decrease in TWIST1 expression whereas only approximately a
two-fold increased expression of TWIST2 comparing H446 to H446-R. In addition, the difference
among resistant and sensitive cell lines was analyzed based on common EMT markers by
Western blot analysis. PC-9 WT was found to have low E-cadherin levels, whereas PC-9R
demonstrated a significantly increased expression (three-fold change) of E-cadherin at the
protein level (Figure 4A,B). On the other hand, H446 WT was found to have a high expression
of vimentin, whereas H446-R demonstrated a reduced expression by three-fold (Figure 4A,B). In
addition, the invasion capacity was also measured for these cell lines. In both cases, the WT was
found to have a significantly greater invasion capability in Matrigel over a 48-hour period than
that of the resistant line (Figure 4C–F).
The development of each MTI-101-resistant cell line required approximately six months
of constant drug pressure with gradual increased increments of dosing before a stable drug
resistant line emerged. In order to determine the stability of this acquisition of a MET
phenotype, the drug pressure of MTI-101 was removed from the resistant cells and analyzed
over a six-month span. The epithelial marker E-cadherin was found to not fully revert back to
the expression level of the WT after six months of being removed from the drug (RFD) by
Western blot analysis (Figure 4G,H). The original Western blots for individual runs can be found
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in Supplemental Figures S8-S10 for Figure 4A along with Supplemental Figure S11 for Figure 4G.
Sensitivity to MTI-101 was analyzed by MTT comparing time from RFD compared to PC-9 WT
and PC-9R. The IC50 values of RFD obtained a slight increase in sensitivity from their original PC9R, but never fully reverted to the PC-9 WT sensitivity at each time point for the six months
tested (Figure 4I). The inability to invade into Matrigel was compared among PC-9 RFD 4, 5 and
6 months to the PC-9 WT and PC-9R. Similarly, the invasion capacity of PC-9 RFD demonstrated
a stable MET phenotype when the drug pressure was removed for six months (Figure 4J).
Together, these data indicate that MTI-101 selects in vitro for a genotype and phenotype that
are predicted to be less invasive.

MTI-101 Treatment In Vivo Recapitulates the In Vitro MET Phenotype
In vivo animal models were conducted to determine whether MT-101 treatment in vivo
induces an MET phenotype. The first study entailed the H446 WT tomato red/LUC cells being
administered via the tail vein in SCID/BEIGE mice. Once mice met the study endpoints per
IACUC protocol, they were euthanized, and the kidneys were extracted for further analysis. The
kidneys were used for to stain for markers of MET in this model because it was the most
common sight of engraftment for all mice in the study, while the lungs had little discernable
tumor burden. The median survival of the treatment group was 89 days, compared to 68 days
for the control, yet was not significant (p-value = 0.13 Figure 5A).
The H&E stains at 40X magnification confirmed that the cancerous portion of the kidney
was being analyzed in these images for both the treatment and control. IHC was used to
compare EMT markers. Vimentin was found to be greatly decreased whereas the membrane
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localization of β-catenin was substantially increased in the treatment group (Supplemental
Figure S12A,B), indicating that the treatment with MTI-101 was consistent with the
transitioning of the cell state toward an epithelial phenotype (Figure 5C). E-cadherin was found
to not be expressed in either group, which was consistent from the Western blots in vitro for
this cell line. The 4X images of three mice from each group analyzed are shown in
(Supplemental Figure S13).
PC-9 cells constitutively expressing tomato red and luciferase were injected via the tail
vein into SCID/BEIGE mice. The two groups consisted of vehicle control and 10 mg/kg MTI-101
treatment three times a week for the duration of the study. A representative IVIS image for the
engraftment of the study is shown in Supplemental Figure S14. PC-9 engraftment was detected
in the lungs of all animals in the study. IVIS imaging indicated that the detectable distal site of
tumor outside of the lung was found in the hind limbs. These multiple tumor sites were
disproportionate between control and drug treatment cohorts during the treatment window,
with three mice containing tumors in the bone within the control group and zero in the
treatment group (Figure 5D), along with significant increases in E-cadherin expression despite
no significant change in vimentin or survival with treatment of MTI-101 compared to the
control (Figure 5B,E,F). Following the end of the study, only one mouse in the MTI-101
treatment group was found to have tumor in the bone. Together, these data indicate that, at a
dose of 10 mg/kg administered three times a week, although there was no significant
difference in survival between treatment and control groups, the drug treatment was shown to
induce a similar change in cell state seen in vitro towards a MET phenotype.
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MTI-101’s Effect in Context with Standard of Care Treatment for Lung Cancer
PC-9 cells are driven by an exon 19 deletion causing EGFR to be constitutively active
[34]. The identification of activating mutations has led to the discovery of EGFR inhibitors,
including the first generation tyrosine kinase inhibitor erlotinib and third generation tyrosine
kinase inhibitor targeting an additional T790M mutation osimertinib [35]. PC-9R cells were
found to have a significantly increased sensitivity to osimertinib and erlotinib single treatment
than that of the parental PC-9 (Figure 6A,B). The IC50 values of the PC-9 WT were 11.59 ± 0.09
and 25.91 ± 0.08 compared to the PC-9R of 4.57 ± 0.07 and 6.60 ± 0.06 nM, respectively,
showing over a two-fold increase in sensitivity with both EGFR inhibitors. There was found to be
no significant difference in sensitivity to cisplatin comparing PC-9 to PC-9R (Figure 6C). These
data indicate that selection for resistance to MTI-101 drives collateral sensitivity to EGFR
inhibitors. To determine whether MTI-101 is synergistic with EGFR inhibitors, PC-9 and
HCC4006 cells were treated with varying concentration of both agents, and the combination
index was determined using CompuSyn software (Version 1.0.1) A combination index
significantly less than 1 is indicative of synergism between the two drugs. Osimertinib and
erlotinib were found to have synergy with MTI-101 with the treatment of PC-9 and HCC4006
cells (Figure 6D,E). The PC-9R maintained a synergistic inhibition of growth when MTI-101
treatment was combined with osimertinib (Figure 6F). In contrast, selection for resistance in the
H446 (SCLC) line did not result in collateral sensitivity to the standard of care agent cisplatin
(Figure 6G). Cisplatin combined with MTI-101 was found to be synergistic in HCC4006, PC-9 and
H446 cell lines (Figure 6H). However, cisplatin was only additive in H446-R, indicating that a
switch in cell state did not maintain synergy with a DNA crosslinking agent (Figure 6I). Together,

74

these data indicate that, for EGFR-driven NSCLC, alternating treatment between MTI-101 and
EGFR inhibitors may be a superior strategy compared to combination strategies. In contrast, a
regimen consisting of a cisplatin and MTI-101 combination may yield the optimal outcome
based on synergy studies and the emerging MTI-101-resistant phenotype.

Discussion
MTI-101 is a cyclic peptide that was developed through the optimization and cyclization
of the linear peptide referred to as HYD-1 [6]. The mechanism of action of this novel class of
molecules includes the induction of cell death via calcium overload, a finding that was
dependent on TRPC1/TRPC4/TRPC5 expression in multiple myeloma cell lines [8]. The cyclized
peptide MTI-101 was shown to have activity using castrate-resistant prostate cancer in vivo
models [9]. In addition, our laboratory recently demonstrated that selection for resistance to
HYD-1, the linear derivative, in myeloma cell lines selected for a compromised cell-adhesionmediated drug-resistant phenotype (CAM-DR) and that HYD-1 and MTI-101 are more potent in
inducing cell death in specimens derived from myeloma patients that have relapsed in therapy
compared to newly diagnosed samples [10]. In this paper, we sought to expand on the
understanding of the activity of MTI-101 in the context of lung cancer. To better understand the
mechanism of action and emergence of resistance, we developed two isogenic drug-resistant
lung cancer cell lines. The first line, H446, is a SCLC cell line that is characterized as PTENdeleted, and contains the overexpression of c-MYC [36,37]. The second cell line is characterized
as NSCLC and harbors the exon 19 deletion of EGFR, leading to a constitutive activation of the
tyrosine kinase EGFR [34]. In the development of MTI-101-resistant lines, morphological
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changes were observed in response to the drug treatment. The parental cell lines were more
spindle-shaped and consisted of an evenly dispersed monolayer in 2D culture. In contrast, the
resistant cell lines display a more cobblestone morphology that clumped to form more cell–cell
interactions, along with forming tighter junctions to the culture dishes, supported with the
notable increased difficulty in trypsinizing these adherent cells. These characteristics of the
resistant cells are consistent with the morphology of more epithelial-like cells that contain tight
sheets of cobblestone morphology to form apicobasal polarity and minimize surface energy
[38,39]. The change in morphology correlated with the functional inhibition of invasion into
Matrigel. It has been shown that transcription factors such as Snail, Twist and nuclear β-catenin
regulate the induction of EMT [40] and can lead to increases in invasive capabilities [41,42], as
seen in the parental cell lines. Using an unbiased analysis of differential gene expression
demonstrated that the hallmark of EMT was reduced in the resistant phenotype. The
conversion to a more epithelial-like phenotype was stable as cells removed from the drug for
six months retained markers of MET and failed to invade Matrigel. These data suggest a
heritable change in cell state, rather than a transient drug-induced state. Importantly,
conversion to a more epithelial-like phenotype was observed using two independent in vivo
models. In the PC-9 cells, this finding correlated with a delay and reduction in detectable bone
metastasis, likely attributed in part to the significantly increased E-cadherin expression. Current
clinical trials are targeting EMT in combination with chemotherapies/targeted therapies in lung
cancer to reduce drug resistance and metastasis [43]. One example is the repurposing of
metabolic inhibitors such as simvastatin for the treatment of lung cancer via the attenuation of
TGFβ1 [44,45]. In addition, a small molecule drug known as moscatilin has been shown to
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reverse EMT in lung cancer cells without inducing cytotoxic effects by suppressing
mesenchymal markers such as vimentin, Snail and Slug [46]. Despite the breadth of research
targeting the EMT pathway in cancer, to the best of our knowledge, the literature has not
presented a drug that selectively kills cancer cells in which a MET phenotype emerges as the
drug-resistant population.
Bioinformatic analysis of the RNA SEQ data demonstrated a stable attenuation of
expression of genes that are associated with the EMT hallmark in both MTI-101-acquired
resistant cell lines. By comparing common differentially expressed genes leading to this
negative EMT enrichment, insight can be gained on the cellular remodeling causative for
transition toward an epithelial phenotype. One transcription factor that may be driving the MET
phenotype with resistance is Twist. The genes Twist1 and Twist2 have both been shown to play
a role in the promotion of EMT and invasion in cancer [47,48]. Twist binds to DNA to repress
the expression of E-cadherin [49], thereby creating dissociation with β- catenin in the
extracellular matrix, causing either the degradation or nuclear localization of β-catenin [40,50].
The activation of the WNT signaling pathway has been shown to activate nuclear β-catenin
localization for the induction of EMT, and it is thus intriguing to speculate that WNT signaling
may be a determinate of sensitivity to MTI-101-induced cell death [51]. A high expression of
Twist1 has also been shown to correlate with the overexpression of fibronectin, vimentin [52]
and SPARC [53], which is consistent with some of the most significantly decreased genes in the
RNA SEQ data of resistant cells in both cell lines. Fibronectin and vimentin have been
extensively studied as mesenchymal markers promoting invasion [20,54–57]. Fibronectin has
also been shown to regulate anoikis resistance by stabilizing cells with the ECM once detached
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from adjacent cells [58]. A significantly decreased fibronectin expression in both resistant lines
could be the cause of increased anoikis-induced apoptosis. There is controversy in the literature
on the role of SPARC in cancer [59], but, specifically for lung cancer, it has been shown to be a
poor prognostic indicator as it promotes tumor metastasis [60,61]. In contrast, it has also been
shown that the loss of E-cadherin itself can induce transcriptional modifications that cause an
induction of EMT in cells [62]. It is important to note that MTI-101 has been shown to shift a cell
state to a more epithelial-like phenotype, but the EMT process has many intermediate stages of
this transition [22]. Further research is needed to determine the heterogeneity of the resistant
population and the existence of subpopulations through single cell sequencing to understand if
an intermediate stage along this process is involved or if it is a full transformation into MET.
Given that Twist was the only EMT transcription factor identified as being downregulated in the
MTI-101 drug-resistant cell lines by gene expression profiling, a partial transition to an epithelial
state is likely. Importantly, when the drug pressure was removed, the transition state toward
MET was stable with respect to the shift in the genotype and phenotype. Clear vulnerabilities
were defined, including an increased susceptibility to anoikis and increased sensitivity to EGFR
inhibitors. It is intriguing to postulate that Twist levels may be used as a biomarker for the
sensitivity of the drug to push cells towards a vulnerable state. The goal of identifying key
changes that could be leading to a less aggressive phenotype is to potentially target or
modulate cancer cells to reduce the incidence of relapse and prolong survival.
Patient relapse is almost always inevitable with current standard of care options for
metastatic lung cancer. The devastation that comes with drug-resistant tumors is (i) surgical
excision of the tumor is not feasible at metastatic sites; and (ii) evasion of drug treatment. MTI-
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101 may be the first of its kind to induce a more favorable and treatable relapsed tumor.
Further studies are required to determine whether the acquisition of resistance to EGFR
inhibitors that occurs via an EMT phenotype can be remodeled to an MET phenotype with
treatment with MTI-101. Once the MTI-101-resistant cancer cells are given a drug holiday
(removed from drug pressure), the shift to an MET phenotype has remained stable for at least
six months. This window would be optimal for additional targeting or chemotherapy treatments
to eliminate these surviving cancer cells. In lung cancer, resistance to standard of care agents
typically yields a more aggressive and drug-resistant EMT phenotype [63,64]. Our findings are
similar to what others have shown, such that the reversal of EMT to MET resulted in resensitizing cancer cells to tyrosine kinase inhibitors such as gefitinib [65]. The alterations
created during MTI-101-acquired resistance enhanced the efficacy of erlotinib and osimertinib
in PC-9. Further studies are required to determine whether alterations of drug treatment (i.e.
EGFR inhibitor followed by MTI-101 and then a repeated cycle of alternating drugs) would
increase survival outcomes in pre-clinical in vivo models of EGFR-driven tumors.
Overall, drug resistance remains a crucial hurdle in the development of new cancer
treatments. Delineating changes that lead to drug evasion and understanding the acquired
phenotype give insight into new possible avenues of targeted or combination therapy to
optimize patient outcomes. MTI-101 has shown promising anti-cancer activity, along with
alterations of a cell state to a more favorable MET phenotype. The acquisition of resistance to
MTI-101 has shown unique qualities that have exposed vulnerabilities to the surviving cancer
cells.
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Conclusion
The emergence of resistance to MTI-101 led to genotypic and phenotypic changes that
correlated with a MET phenotype using both in vitro and in vivo models in PC-9 and H446 cells.
Phenotypic modifications included increased cell–cell connections through morphological
changes and increased expression of epithelial-like proteins, while decreasing the expression of
mesenchymal-like proteins with a reduction in invasion. The stability of the transformed state
in vitro is intriguing and could allow for a double bind therapeutic strategy where the goal is to
switch between cell states EMT-MET to keep the tumor from rapidly escaping targeted
therapies, such as EGFR inhibitors. Interestingly, the phenotypic selection pressure was survival
despite MTI-101 treatment, and this MET population arose concurrently. More studies are
required to determine if MTI-101 depletes the EMT population, leading to the emergence of an
MET genotype, or, rather, if selecting resistance coincides with the attenuation of calcium
signaling and, conversely, if robust calcium signaling is required to support the EMT genotype
and phenotype. Resistance to MTI-101 also conferred collateral sensitivity to EGFR inhibitors
for PC-9 cells. In addition, MTI-101 combination therapy with standard of care agents erlotinib,
osimertinib and cisplatin all displayed synergistic activity in eliminating the cancer cells. These
alterations that arise in PC-9 and H446 cells with the sole pressure of MTI-101 suggest a shift to
a clinically favorable and long-term mesenchymal-to-epithelial transition that could give insight
into novel anti-cancer therapeutic targets and combination strategies to optimize patient
outcomes. Future studies are required to determine if following treatment in vivo with a
standard of care agent such as erlotinib with MTI-101 and the subsequent emergence of
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resistance is sufficient to drive the tumor population back toward drug sensitivity and a more
epithelial cell state.

Supplementary Materials:
The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/cancers14133062/s1, Figure S1: Bioinformatic Analysis of RNA
SEQ Predicts a Shift toward a MET Phenotype with Acquired Resistance to MTI-101 in H446 vs.
H446- R. EMT genes’ fold change between H446 and H446-R; SPARC-FDR = 33.09 × 10−4, VIMFDR = 6.36 × 10−4, FN1- FDR = 2.81 × 10−4, TWIST1- FDR = 1.60 × 10−4; Figures S2–S4: Original
Western blots of TWIST1 (n = 3); Figures S5–S7: Original Western blots of TWIST2 (n = 3);
Figures S8–10: Original Western blots for Figure 4A (n = 3); Figure S11: Original Western blot of
Figure 4G; Figure S12: H446 In Vivo Single Treatment MTI-101. (A) B-catenin localized heavily
inside the cell in the one kidney of the control group with B-catenin presence. (B) A
representative image of the treatment group containing B-catenin almost exclusively
extracellularly; Figure S13: All H446 In Vivo H&E and IHC Images at 4× Magnification. Kidneys
were taken from the H446 in vivo study, fixed in formalin, paraffin blocked and then sliced for
slides to analyze EMT markers. Three control and three treatment (10 mg/kg MTI-101) mice
were picked at random to compare EMT markers. (A) H&E, (B) E-cadherin, (C) vimentin, (D) Bcatenin; Figure S14: Representative IVIS Images of Tumor Location for each In Vivo Study.
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Figure Legends
Figure 1: Development of Isogenic MTI-101 Resistant Lung Cancer Cell Lines. (A) 24 Hour MTTs
were performed with varying drug doses of MTI-101 comparing H446 to its respective resistant
cell line. IC50 values were reported as an average n = 3 independent experiments. (B) 24 Hour
MTTs were performed with varying drug doses of MTI-101 comparing PC-9 to its respective
resistant cell line. IC50 values were reported as an average n = 3 independent experiments. (CD) Resistance to MTI-101 induces cell morphological changes to more adherent epithelial like
cells compared to the respective WT on a microscope at 20x magnification. (E-F) Anoikis assay
comparing WT to respective resistant cell line for apoptotic percentage in low attachment
plate. Results reported as n = 3. Error bars represent SEM (significances denoted * for p<0.05,
two-tailed T-test).

Figure 2: Transcriptome analysis indicated a downregulation in EMT in MTI-101 resistant
lines. (A) PCA Plot of all Cell Lines based on gene expression. (B-D) GSEA analysis of genes
sorted based on fold changes of PC-9R vs PC-9 (B), H446-R vs H446 (C), or PC-9R RFD vs PC-9 (D)
from high (red) to low (blue) against MSigDB hallmark gene set “epithelial mesenchymal
transition” (vertical bars). NES: normalized enriched score (E) Venn Diagram analysis of DE
genes predicted for each resistance lines vs corresponding WT. (F) Bar plot for expression
values of SPARC, VIM, FN1, TWIST2, and PLOD2 across PC-9, RFD, and PC-9R; FDR for
differential expression from EdgeR indicated (G) Individual genes (SPARC, VIM, FN1,
ACS3/TWIST1, TWIST2, and PLOD2) split by median on all lung cancer patient data and
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predicted clinical prognosis in lung cancer. TWIST1 (ACS3), FN1 and PLOD2 are poor prognostic
indicators for clinical outcome in lung cancer.

Figure 3: MTI-101 acquired drug resistant lines demonstrate decreased expression of EMT
transcription factor TWIST at the protein level. (A) Western Blot probing for TWIST1 in WT and
Resistant Cells; Western Blot images were from the same blot but were spliced and rejoined
between PC-9R and H446 samples in TWIST1 and β-actin images to remove protein standard
marker for clarity (B) Quantification of Western Blot showing significant decreased protein
expression of TWIST1 in H446-R cells compared to H446 (C) Western Blot probing for TWIST2 in
WT and Resistant Cells (D) Quantification of western blot showing significant decrease in
protein expression of TWIST2 in PC-9 resistant cells compared to PC-9 WT. Completed as n = 3
independent experiments with reproducible representative images displayed for Western Blots.
Error bars represent SEM (significances denoted * for p<0.05, two-tailed T-test).

Figure 4: Emergence of Resistance to MTI-101 Selects for a Stable Phenotype Associated with
Diminished Invasive Capacity and Increased Expression of Epithelial Markers. (A) PC-9 and
H446 WT were compared to their respective MTI-101 resistant lines with respect to EMT
protein markers. E-cadherin is an epithelial marker and was found to be overexpressed in the
PC-9R cell line compared to WT. Vimentin is a mesenchymal marker and was found to be
substantially decreased in H446 resistant cells compared to WT. Both corroborate a transition
to a more epithelial like cell phenotype (MET). (B) Quantification of Western Blot (C) PC-9
Invasion assay comparing the WT to resistant cells’ ability to invade into the Matrigel over a 48-
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hour time period (D) Quantification of PC-9 Invasion (E) H446 Invasion assay comparing the WT
to resistant cells’ ability to invade into the Matrigel over a 48-hour time period. (F)
Quantification of H446 invasion (G) Western blot comparing E-Cadherin expression when PC-9R
is removed from drug pressure over a 6-month period (H) Quantification of Western Blot for ECadherin in PC-9 removed from drug (RFD) (I) IC50 values of MTTs run with MTI-101 treatment
comparing PC-9 to its respective resistant and RFD cells (J) Invasion assay showing lack of
invasion of PC-9 RFD even after six months compared to PC-9 wild type cell line. Completed as n
= 3 independent experiments, reproducible representative images shown for invasion images
and Western Blots. Error bars represent SEM (significances denoted * for p<0.05, two-tailed Ttest).

Figure 5: MTI-101 Treatment In Vivo Recapitulates the In Vitro MET Phenotype. Kidneys were
taken from the H446 in vivo study, fixed in formalin, paraffin blocked and then sliced for slides
to analyze EMT markers. The lungs of the PC-9 study went through the same process. Three
control and three treatment (10 mg/kg MTI-101 3 times per week IP injection) mice were
picked at random from H446 and six of each in PC-9 were picked to compare EMT markers. (A)
Survival curve shows no significant differences between MTI-101 treatment and control (n = 14,
p>0.05 Log Rank Test) (B) Survival curve shows no significant differences between treatment
and control in PC-9 study (n = 21, p>0.05 Log Rank Test) (C) H446 study tumor portions of the
kidneys stained with H&E to confirm presence of tumor and EMT markers (vimentin, E-Cadherin
and β-catenin) demonstrates in vivo tumor transformation to MET with chronic treatment with
10 mg/kg of MTI-101 (D) PC-9 study quantity of mice detected with tumor in the bone over
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time course of study detected by IVIS and confirmed by H&E stains (E) Quantification of Ecadherin and Vimentin in IHC stains of PC-9 study (n=6 tissues stained from control and drug
treated cohort) (F) PC-9 H&E and IHC stains of lungs show presence of tumor and a significant
increase in E-cadherin expression but no significant change in vimentin or b-catenin between
control and MTI-101 treatment. Average representative image shown for all IHC. Tumors
engrafted for 4 weeks (H446) and 3 weeks (PC-9) prior to drug treatment. Error bars represent
SEM (significances denoted * for p<0.05, two-tailed T-test).

Figure 6: Selection for resistance to MTI-101 demonstrates collateral sensitivity to EGFR
inhibitors but not Cis-Platinum treatment. 72 Hour MTT Assays were performed with the single
treatment of Osimertinib, Erlotinib, or Cisplatin comparing WT to their respective MTI-101
Resistant Cell Line. IC50 values comparing PC-9 to PC-9R were significant with Osimertinib and
Erlotinib (significance p<0.05,T-test) (A-C,G). 72 Hour MTTs using combination therapy with
MTI-101 in PC-9, HCC4006 and PC-9R demonstrate synergism with EGFR inhibitors (D-F). 48
hour MTTs using combination therapy with MTI-101 and Cisplatin were synergistic in HCC4006,
PC-9, and H446 cells (H) and additive in H446-R (I). Drug combination effects were determined
by using CompuSyn software analysis. Shown is the mean CI of N=3 independent experiments.
Error bars represent SEM (significances denoted * for p<0.05, two-tailed T-test).
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Abstract
A first-in-class cyclic peptide known as MTI-101 was found to selectively target and
induce necrotic cell death in lung cancer cells correlated with concurrent calcium flux and cAMP
activation. MTI-101 was shown to deplete ER calcium stores, followed by increased
cytoplasmic calcium. Resistance to MTI-101 induced death was found to have decreased
cationic channels, drug binding, and downstream effectors such as calcium and cAMP that
could play an essential role in drug evasion. MTI-101 death was exacerbated with a CAM
inhibitor (W7) and protected with an exogenous activation of CAM using CALP1 (CAM agonist).
Meanwhile, inhibition of AC and cAMP activation was found to have no effect on MTI-101 cell
death. Understanding the mechanism of MTI-101 could give insight into a novel GPCR target
and its role in cancer. Additionally, the mechanism selecting for decreased calcium signaling
could produce a less proliferative cell state leading to improved therapies and novel drug
discoveries.

Introduction
As stated above, calcium seems to play a major role in MTI-101 induced cell death in
multiple cancer types. Additionally, calcium remains essential in the progression of an
epithelial-to-mesenchymal transition (EMT) in cancer by participating in roles including but not
limited to remodeling of the extracellular matrix (ECM), invasion, G-protein coupled receptor
(GPCR) signaling, immune evasion, and drug resistance[1]. The overexpression of calcium
channels has been correlated with increased metastasis and proliferation. For example, ORAI3
and STIM1 have been found to mediate TGF-b induced Snai1 expression for the progression of
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EMT[2]. Furthermore, TRPC1-6 overexpression was found to increase proliferation and invasion
in several cancer types illustrating the importance these cationic channels play in EMT[3].
Given these findings, calcium channels are being viewed as potential targets for novel anticancer therapeutics. The role of calcium in current standard of cares is also being incorporated
in the development of new combination therapy strategies along with giving insight into
mechanisms of drug resistance. Targeted therapies exploit differences between healthy and
malignant cells to selectively abrogate the unique and essential functions for cancer cells to
survive. This excessive need for high levels of calcium can create vulnerabilities to changes in
intracellular calcium within cancer cells that leaves them much more susceptible to calcium
targeting therapies than the non-malignant cells. Recent studies have shown increased efficacy
of standard of cares for advanced stage prostate cancer such as docetaxel and enzalutamide
with the concurrent activation of a calcium influx channel known as TRPM8 using agonist such
as menthol[4]. The role of calcium in MTI-101 induced cell death will be explored throughout
this paper.
One way in which calcium signaling may be activated is through receptors located
throughout the cellular membrane known as GPCRs. There are upwards of 1000 different
GPCRs that each have a unique ligand and a particular signal[5]. GPCRs remain the most
prominent druggable targets approved by the FDA with roughly 35% of drugs targeting these
receptors[6]. This group of receptors has a variety of classes in humans including rhodopsin,
secretin, glutamate, adhesion/taste, cAMP, frizzled/smoothened. Many of these receptors
don’t currently have known ligands and are referred to as orphan GPCRs. The various signaling
pathways of each GPCR is dependent on its bound G-proteins on the intracellular domain. The
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different G protein subunits include Gas, Gaq, and Gai. The Gaq is capable of activating the
Phospholipase C (PLC) signaling pathway that utilizes calcium as a second messenger for its
cellular effect[7]. The Gas and Gai work in opposition of each other as Gas activates adenylyl
cyclase (AC) that utilizes cyclic adenosine monophosphate (cAMP) as a second messenger while
Gai negatively regulates AC to decrease cytosolic cAMP[8]. Further research is needed to
determine the role these receptors play in physiological and pathological conditions.

Materials and Methods
Cell Culture/Reagents- PC-9 (Sigma #90071810) and H446 (ATCC #HTB-171) lung cancer cell
lines were used as parental cell lines. MTI-101 resistant cell lines PC-9R and H446-R were
developed with chronic exposure to MTI-101 over a 6-month period. All cell lines were
maintained in RPMI-1640 L-Glutamine with 10% Fetal Bovine Serum, and 1%
penicillin/Streptomycin. Resistant cell lines were maintained with a constant level of MTI-101
in culture media (60µM for PC-9R and 40 µM for H446-R). All cell lines were tested for
mycoplasma every six months, and STTR analysis was performed on a yearly basis.
Calcium Flux Assay- (ER calcium indicator R-CEPIA1er) PC-9 WT and PC-9R cells both
transfected with mCherry Calcium-measuring organelle-Entrapped Protein IndicAtor 1 in the ER
(R-CEPIA1er) were split and plated at a density of 10,000 cells per well in a 96 well plate with
100 uL complete media RPMI (+FBS, +P/S) and allowed to adhere and grow for 24 hours. The
media was then aspirated off and the cells were washed with imaging media. 40 uL of imaging
media containing 1x Dapi was added to each well and a baseline image was taken using Biotek
Cytation 5 imaging system. Then, the control group received 40 additional uL of 1x Dapi
imaging media and the treatment groups received imaging media containing 30 uM MTI-101.
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The cells were imaged every 30 seconds for one hour and fluorescence intensity was analyzed
for Dapi and CEPIA. (CEPIA excitation and emissions: 531 nM/593 nM wavelength)
(Cytoplasm Calcium Indicator X-Rhod-1 AM) PC-9 WT and PC-9R cells were split and
plated at a density of 6000 cells/well in a clear, black bottom 384 well plate with 100 uL RPMI
media (+FBS, +P/S) and allowed to adhere to plate and grow for 24 hours. The media was
aspirated off and the cells were incubated at 37 °C with 4 uL/mL X-Rhod-1 AM (80 uL per well)
for 45 minutes. After incubation, the dye was aspirated off and 80 uL RPMI media (+FBS, +P/S)
was added to each well and incubated again at 37 °C for 30 minutes. Media was aspirated off
and 40 uL imaging media containing 1x Dapi was added to each well and a baseline image was
taken using Biotek Cytation 5 imaging system. Then, the control group received 40 additional
uL of 1x Dapi imaging media and the treatment groups received imaging media containing 30
uM MTI-101. The cells were imaged every 30 seconds for one hour and fluorescence intensity
was analyzed for Dapi and X-Rhod-1 AM. (X-Rhod-1 AM excitation and emissions: 580 nM/602
nM wavelength).
cAMP Signaling Assay-The fluorescent cAMP indicator (flamindo2) consists of a YFP (Citrine)
fused with a cAMP binding domain mEPAC1 near the chemophore. When cAMP binds to cAMP
binding domain, it induces a conformational change that reduces the YFP significantly. At
saturation of cAMP (1mM), the YFP signal is reduced by 75% (4-fold). The flamindo2 plasmid
was transfected in PC-9 WT and Resistant cells via electroporation and sorted for YFP+ by flow
and gated with normal PC-9 cells. 8-bromo cAMP (SelleckChem, S7857) is a cell permeable
cAMP analogue that still activates PKA (more cell permeable and phosphodiesterase resistance
than cAMP) that was used as a positive control to show decreased YFP with increased cAMP
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binding. PC-9 WT cells transfected with Flamindo2 were split and plated at a density of 10,000
cells per well in a clear, black bottom 384 well plate with 100 μL RPMI media (+FBS, +P/S). The
cells were allowed to adhere and grow for 24 hours. Then, the media was aspirated off, and 40
μL 1X DAPI/Imaging Media was added to each well. A baseline image was taken using the
Biotek Cytation 5 imaging system. The control group then received 40 additional μL of 1X
DAPI/Imaging Media, and the treatment groups received 30 μM MTI-101/Imaging Media. The
cells were imaged every 3 minutes for one hour, and fluorescence intensity was analyzed for
YFP and DAPI (Flamindo2 excitation and emission spectra: 504/523nM).
cAMP Inhibition Assay
PC-9 WT cells were split and plated at a density of 10,000 cells per well in a clear, black bottom
384 well plate with 100 μL RPMI media (+FBS, +P/S). The cells were allowed to adhere and grow
for 24 hours. The media was then aspirated off. Next, half the cells were incubated at 37 °C
with 150 μM of a cell permeable non-competitive adenylyl cyclase (AC) inhibitor SQ22536
(Tocris Cat #1435) in RPMI media (80 μL per well) for 45 minutes. The remaining cells were
simultaneously incubated at 37 °C with RPMI media for 1 hour. After incubation, the media and
SQ22536 were aspirated off, and 40 μL of 1X DAPI/Imaging Media (experimental control) or
SQ22536 in 1X DAPI/Imaging Media were added. A baseline image was taken using the Biotek
Cytation 5 imaging system. Then, the control group received 40 additional μL of 1X
DAPI/imaging media, the SQ22536 single treatment group received 40 additional μL of
SQ22536 in 1X DAPI, and the MTI-101 treatment groups received 1X DAPI containing 30 μM
MTI-101. The cells were imaged every 3 minutes for one hour, and fluorescence intensity was
analyzed for YFP and DAPI. There were four groups analyzed: 1X DAPI, SQ22536 in 1X DAPI,
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MTI-101 in 1X DAPI, and MTI-101 and SQ22536 in 1X DAPI. Cell death was compared among the
groups.
Radioactive labeling of MTI-101- MTI-101 was synthesized as previously described, and
weighed (2 mg), dissolved in 1 mL freshly distilled tetrahydrofuran (THF), and 0.2 mL
trichloroacetic acid added. After the peptide had dissolved, 50 uL of a 1 mCi/mL solution of
[3H]H2O (PerkinElmer) was added to the solution, and incubated while stirring for 2 hours. After
two hours, a spatula of sodium bicarbonate (NaHCO3) was added and stirred until the evolution
of neutralizing gas was evident. The THF was evaporated, and the peptide dissolved in 100%
ethanol, cleaned using a C18 syringe column, and counted to validate labeling. [3H]MTI-101
was resuspended in ethanol to give a final concentration of 2 mg/0.5 mL.
Binding Assay- Two binding assays were performed to analyze changes in cells binding to MTI101. The first binding assay used MTI-101 radiolabeled with tritium and standardized by
protein content. Cells were seeded into a 6-well plate at 500,000 cells per mL with RPMI media.
[3H]MTI-101 was added to the cells at 10 uL per well. After incubation period of 15 min, the
media was aspirated, and the cells were washed with phosphate buffers saline (PBS) pH 7.4.
RIPA buffer (500 uL) was added to each well, triturated, and placed into a 7 mL scintillation vial.
Scintillation cocktail was added and counted using a scintillation counter (PerkinElmer).
The second binding assay used the linear peptide HYD1 conjugated with a GFP to make
FAM-HYD1. Equal number of cells were plated and washed with a membrane dye (WGA, Texas
Red), washed with PBS and then washed with 0.125 mg/mL FAM-HYD1 for 15 minutes. Cells
were washed one last time with PBS and then fixed in 2 % PFA. Images were taken on EVOS
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using GFP and Texas Red channels merged to show total amount and localization of FAM-HYD1
binding compared between WT and resistant cells.
Calmodulin Inhibition Assay- W7 CAM Inhibitor
PC-9 WT cells were split and plated at a density of 10,000 cells per well in a clear, black bottom
384 well plate with 100 uL RPMI media (+FBS, +P/S). The cells were allowed to adhere and grow
for 24 hours. The media was then aspirated off. Next, half the cells were incubated at 37 °C
with 25 μM W7 (Tocris Cat#0369) in RPMI media, a cell-permeable CAM antagonist (80 μL per
well) for 1 hour. The remaining cells were simultaneously incubated at 37 °C with RPMI media
for 1 hour. After incubation, the media and W7 were aspirated off, and 40 μL of 1X
DAPI/Imaging Media (experimental control) or W7 in 1X DAPI/Imaging Media were added. A
baseline image was taken using the Biotek Cytation 5 imaging system. Then, the control group
received 40 additional μL of 1X DAPI/Imaging Media, the W7 single treatment group received
40 additional μL of W7 in 1X DAPI, and the MTI-101 treatment groups received 30 μM MTI101/Imaging Media. The cells were imaged every 2 minutes for one hour, and fluorescence
intensity was analyzed for DAPI. There were four groups analyzed: 1X DAPI, W7 in 1X DAPI,
MTI-101 in 1X DAPI, and MTI-101 and W7 in 1X DAPI. Cell death was compared among the
groups.
Calmodulin Agonist Assay- CALP1 CAM Agonist
PC-9 WT cells were split and plated at a density of 10,000 cells per well in a clear, black bottom
384 well plate with 100 uL RPMI media (+FBS, +P/S). The cells were allowed to adhere and grow
for 24 hours. The media was then aspirated off. Next, half the cells were incubated at 37 °C
with 100 μM CALP1 in RPMI media, a cell-permeable CaM agonist (80 μL per well) for 1 hour.
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The remaining cells were simultaneously incubated at 37 °C with RPMI media for 1 hour. After
incubation, the media and CALP1 were aspirated off, and 40 μL of 1X DAPI/Imaging Media
(experimental control) or CALP1 in 1X DAPI/Imaging Media were added. A baseline image was
taken using the Biotek Cytation 5 imaging system. Then, the control group received 40
additional μL of 1X DAPI/Imaging Media, the CALP1 single treatment group received 40
additional μL of CALP1 in 1X DAPI, and the MTI-101 treatment groups received 30 μM MTI101/Imaging Media. The cells were imaged every 2 minutes for two hours, and fluorescence
intensity was analyzed for DAPI. There were four groups analyzed: 1X DAPI, CALP1 in 1X DAPI,
MTI-101 in 1X DAPI, and MTI-101 and CALP1 in 1X DAPI. Cell death was compared among the
groups.
RNA Extraction- Quadruplicates of RNA were extracted from each WT and resistant lines of PC9 and H446 using RNeasy Plus Mini Kit (Qiagen, cat#74104). 2-3 million cells were isolated in a
dry pellet and resuspended and RNA was initially extracted using Trizol, and then further
purified using the Qiagen RNeasy Mini Protocol and RNA was stored at -80 degrees. The same
RNA isolation procedure was performed for the PC-9 4, 5, and 6 months removed from drug
(RFD).
RNA-Seq Data Analysis- RNA-Seq libraries were sequenced at Marshall University Genomics
Core with Illumina NextSeq 2000. Pair-end RNA-SEQ short reads were aligned to the whole
human reference genome (hg38) by subread v2.0.1[9]. The total number of reads aligned to
transcripts at gene level were summarized by featurecounts from Rsubread v2.2.0[10] with
built-in RefSeq gene annotation. Gene expression level was quantified by RPKM (reads per
kilobase of exon model per million mapped)[11]. We used edgeR v3.30.3[12] to define

110

differentially expressed (DE) genes with the following criteria: p-value < 0.05, fold change >1.5,
and CPM (count per million; log2)> 0. To determine the relationship between expression
changes of PC-9 and H446 to their MTI-101 resistant counter parts, we employed Gene Set
Enrichment Analysis through GSEA v4.0.2. We created three “rnk” files based on fold change of
expression (treatment vs baseline) for the following comparisons: PC-9R vs PC-9, H446-R vs
H446 and PC-9 RFD vs PC-9; a “rnk” file consist of one column for gene symbol and another for
fold-change of expression. The rnk file was then supplied as input to GSEA to determine the
significance of a preferential expression for selected gene sets from MSigDB in treatment
condition over the baseline, or vice versa.

Results
MTI-101 Induces Intracellular Calcium Flux from ER Stores Correlated with Death
It has previously been reported that MTI-101 induced cell death in U266 and H929
multiple myeloma cells through calcium flux leading to necrotic cell death[13]. To analyze this
hypothesis in lung cancer, ER and cytoplasmic calcium levels were quantified during treatment
of MTI-101. A genetically engineered probe called R-CEPIA1er was utilized to understand how
ER calcium levels were altered by MTI-101. The R-CEPIA1er plasmid contains a calmodulin
binding domain, ER localization sequence, and mCherry for red fluorescent protein (RFP)
visualization and quantification. This plasmid was transfected via electroporation in the PC-9
WT and PC-9R cell lines and sorted by flow on RFP. When calcium binds to the calmodulin
domain in the ER, the RFP fluoresces at five times the intensity to aid in the quantification of
calcium level changes. The imaging cell media also contained 1X Dapi that lightly stains DNA
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blue, but brightly fluoresces when the cell membrane becomes permeable after death.
Thapsigargin (SERCA blocker) was used as a positive control to validate the system since
thapsigargin in the literature is known to deplete ER stores but also block the calcium reentry
into the ER[14].
Images were taken at 5-minute intervals of the PC-9 WT CEPIA with a negative vehicle
control of 1X Dapi, a positive control Thapsigargin (SERCA channel blocker) and a 30 µM MTI101 treatment group (Figure 1A). PC-9 WT CEPIA was compared to PC-9R CEPIA. The WT cells
showed a significant decrease of ER calcium after about five minutes of MTI-101 treatment
illustrating the MTI-101 is capable of signaling for the depletion of ER calcium stores. Then,
about fifteen minutes post treatment with MTI-101, calcium stores were replenished and
correlated with an increase in Dapi intensity indicative of cell death in a representative single
cell tracing (Figure 1C). The PC-9R CEPIA cell line showed no calcium flux with the same
treatment of MTI-101 (Figure 1F). Thapsigargin caused a rapid decrease of calcium ER stores
without replenishment or cell death, validating the experiment for both the WT and resistant
cells (Figure 1D, Figure 1G). An average of 30 cells for each group was also quantified using RFP
intensity comparing the three experimental groups of each cell line to show significance of
calcium flux with MTI-101 treatment only in the PC-9 WT CEPIA (Figure 1E, Figure 1H). A high
intensity Dapi threshold was established to quantify the comparison between WT and Resistant
cell lines’ treatment and control groups. Significant death only occurred in the PC-9 WT CEPIA
treatment group over the sixty-minute time analysis showing cell death occurred following
calcium flux (Figure 1B).

112

MTI-101 Induces Cytoplasmic Calcium Flux Correlated with Cell Death
To increase the understanding of the mechanism of MTI-101 induced cell death,
cytoplasmic calcium levels were also analyzed. X-Rhod-1 AM is a water soluble, cell permeable
calcium indicator that combines the 8-coordinate tetra carboxylate chelating site with a
xanthene chromophore to give a rhodamine like fluorophore that was used as a molecular tool
to quantify calcium changes in the cytoplasmic with treatment of MTI-101. PC-9 WT cells
incubated with X-Rhod-1 AM were found to have a significant spike of cytoplasmic calcium
within a few minutes of treatment of MTI-101 followed by a gradual sustained increase in
calcium correlated with cell death compared to that of the no treatment vehicle control in
single cell analysis (Figure2A, Figure 2B) and N=30 (Figure 2C). In contrast, the PC-9R cells were
found to have no significant cytoplasmic calcium flux with treatment of MTI-101 nor cell death
compared to its respective vehicle control in single cell analysis (Figure 2D, Figure 2E) and N=30
(Figure 2F) potentially playing a role in survival.

Transcriptome Analysis Substantiates Decreased Cationic Channel Activity in Resistance and
Specifically TRP1,4, and ORAI1
Full genome RNA SEQ was conducted on PC-9 WT v Resistant cell lines. A heat map was
constructed and analyzed for cation channel expression (Figure 3A). It was found that PC-9R
cells had significantly reduced overall cation channel expression compared to PC-9. It was also
found by analyzing individual cation channels that have been previously reported to be involved
in the mechanism of MTI-101[15] such as TRPC1, TRPC4, and ORAI1 to be consistently down in
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the PC-9R (Figure 3B-D). This data coupled with the calcium flux results support that resistant
cell alterations are occurring upstream of calcium signaling that may be responsible for survival.
Resistance to MTI-101 Correlated with Decreased Drug Binding
Drug binding of MTI-101 was analyzed on PC-9, PC-9R, and BEAS-2B cells to potentially
delineate changes on the cell surface that may lead to resistance. Both PC-9R and H446-R cells
were found to have significantly decreased drug binding in an MTI-101 radiolabeled drug
binding assay using tritium and standardized by protein concentration compared to their
respective WT cells (Figure 4A, Figure 4B). The linear peptide of MTI-101 known as HYD1 was
conjugated with FAM (GFP) and counterstained with a membrane dye WGA (Texas Red) to
visualize localization and quantification of drug binding. PC-9R had substantially less drug
binding than the PC-9 cells (Figure 5). The binding appeared to be extracellular and intracellular
when the WGA was merged with the FAM-HYD1 stains. The intracellular binding could be due
to significant overexpression of b-Arrestin in PC-9 and H446 compared to resistance that causes
the receptor binding to agonist to be endocytosed (Supplemental Figure 1). BEAS-2B was also
shown to have significantly less binding than the WT cancer cells lines (Figure 5), which would
be consistent with lack of efficacy of MTI-101 in normal bronchial epithelial cells[16].

MTI-101 Induces cAMP Activation
PC-9 WT and Resistant cells were transfected with a cAMP detecting probe that
decreases YFP signal when bound to cAMP. MTI-101 was found to induce cAMP activation in
PC-9 WT similar to the positive control 8-bromo cAMP and significantly different than the
negative vehicle control (Figure 6A-C). PC-9R cells illustrated no change in cAMP activity with
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MTI-101 treatment (Figure 6D-F). This data indicates that MTI-101 induces cAMP activation in
WT cells that is blocked in resistance. In this manner, MTI-101 has been shown to activate
calcium signaling concurrently with cAMP which is a unique characteristic of GPCRs. Therefore,
MTI-101 was proposed to have a mechanism in lung cancer of binding to a GPCR as an agonist
that is capable of activating a calcium signaling pathway simultaneously with a cAMP signaling
pathway shown in Figure 7. Inhibition of individual pathways will be analyzed to understand
how MTI-101 induces cell death.

MTI-101 Death is not Correlated with Death Through cAMP Activation
An AC inhibitor (SQ22536) was used in combination to MTI-101 to show its effect on
MTI-101 downstream signaling and its effect of death. The AC inhibitor is a cell permeable
molecule that causes competitive inhibition of ATP binding to AC preventing the conversion of
ATP to cAMP shown in Figure 8A. The 8-bromo cAMP (positive control) and MTI-101 single
treatment were once again able to show that MTI-101 induced cAMP activity that was inhibited
by the combination of MTI-101 treatment with the AC inhibitor similar to that of the negative
vehicle control (Figure 8B). Interestingly, the blockage of MTI-101 cAMP induced activity did
not alter cell death in PC-9 WT cells (Figure 8C).

The Effect of CAM on MTI-101 Induced Cell Death
PC-9 WT cells transfected with R-CEPIA1er, and PC-9 WT cells incubated with were both
utilized in conjunction with a CAM inhibitor and agonist to understand how MTI-101’s
mechanism would be altered in respect to an intracellular calcium regulator. The CAM agonist
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(CALP1) is capable of binding to CAM to induce its active conformation. CAM’s active
conformation has been shown to prevent SOCE along with IP3R inhibition acting as a negative
regulator of calcium flux. The proposed mechanism is the activation of CAM by an agonist will
prevent MTI-101 induced calcium flux (Figure 9A). The CAM agonist combined with MTI-101
was found to completely protect cells from MTI-101 cell death compared to MTI-101 treatment
alone (Figure 9C). The CAM agonist alone was also found to have no cytotoxic cellular effects
as a single agent with no significant changes in death from the negative vehicle control (Figure
9C). At high dose MTI-101 treatment, CALP1 was found to significantly increase survival up to
24 hours (Supplemental Figure 2). In opposition, a CAM inhibition (W7) was utilized to see how
antagonism of CAM would alter MTI-101 induced cell death. The CAM inhibitor is a cell
permeable molecule that binds to CAM to prevent calcium binding and CAM activation
essentially removing the negative regulator of calcium from involvement within the cell (Figure
9B). The CAM inhibitor alone was not capable of inducing cell death, but in combination with
MTI-101 treatment the CAM inhibitor showed significantly increased cell death compared to
MTI-101 treatment alone (Figure 9D). Therefore, the activation of CAM was shown to protect
from MTI-101 induced cell death while antagonism of CAM exacerbates death.

CAM Agonist Partially Protects from MTI-101 Induced Calcium Flux Correlated with Survival
The PC-9 WT cells incubated with X-Rhod-1 AM and the PC-9 WT CEPIA cells were
analyzed for calcium flux using the CAM agonist. MTI-101 combined treatment with the CAM
agonist significantly delayed ER calcium depletion and reduced total ER calcium depletion
compared to MTI-101 single treatment in single cell analysis (Figure 10A) and N=30 (Figure
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10B). In addition, combined CAM agonist and MTI-101 treatment delayed initial calcium flux
and reduced overall cytoplasmic calcium increases when compared to MTI-101 single treatment
in single cell analysis (Figure 10C) and N=30 (Figure 10D). The CAM Inhibitor combined with
MTI-101 was found to have no significant changes in cytoplasmic calcium fluctuations
compared to MTI-101 single treatment (Figure 11).

Preliminary Evidence for MTI-101 Binding Target with GPCRs
Full genome RNA SEQ was compared between PC-9, PC-9R, PC-9 RFD (removed from
drug), H446, and H446-R with respect to significant differentially expressed GPCRs and was
compiled in a heat map (Figure 12). The most interesting genes for GPCRs that were decreased
in both resistant cell lines compared to their respective WTs and were retained down in the PC9 RFD. The PC-9 RFD were characterized in Jones et al 2022 [16] and arose from the PC-9R cell
line that was removed from MTI-101 drug pressure for 4, 5, and 6 months. A variety of Frizzled
receptors (FZD2, FZD6, and FZD7) kept reappearing at disproportionate rates to other types of
GPCR receptors that were decreased in expression in resistant cell lines and therefore were
selected as top candidates for an MTI-101 binding target.

Discussion
Calcium remains tightly regulated in healthy cells, whereas cancer could come at a cost
of decreasing calcium homeostasis pathways that lead to an abundance of calcium needed for
proliferation and invasion of malignant cells. Targeting calcium pathways have been
increasingly important with novel combination therapies that have proved to increase the
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survival of patients[17]. RNA Sequencing data suggest that cationic channel activity was
significantly decreased in resistance compared the WT PC-9 cancer cells. Previously, MTI-101
cell death was found to be blocked with inhibition of channels such as TRPC1, TRCP4, and
ORAI1[15]. Interestingly in lung cancer, MTI-101 was found to deplete ER calcium stores, while
increasing cytoplasmic calcium levels in lung cancer similar to the proposed mechanism in
multiple myeloma[13]. Two spikes in calcium flux in the cytoplasm with MTI-101 treatment
illustrate an initial source likely originating from ER stores and an additional source most likely
originating from extracellular supply introduced via TRPC and ORAI1 channels. This process was
found to be blocked in the MTI-101 resistant cells, likely suggesting upstream cell alterations
that are leading to drug resistance.
Variation in drug binding was a forefront suspect that could lead to resistance. MTI-101
was found to be significantly hindered in binding to H446-R and PC-9R compared to their
respective WTs. Binding was significantly less in the healthy BEAS-2B compared to both WT
cancer cell lines as well which could be an explanation for the lack of efficacy seen in vitro of
MTI-101. Resistance correlated with inhibited downstream effectors along with decreased
binding suggestive that the binding target for MTI-101 could be downregulated, posttranslationally modified to hinder localization to the membrane, or mutated to prevent drug
binding.
In order to delineate the type of receptor that may be involved in MTI-101 induced cell
death, changes in the second messenger cAMP were also analyzed to determine if a GPCR may
be the binding target of MTI-101. Currently almost half of all FDA approved drugs target a
GPCR[5] and a unique trait to these receptors is the capability of activating calcium and cAMP
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simultaneously as downstream effectors for signal transduction[18]. MTI-101 was found to
activate cAMP activity that was also blocked in resistant cells. Given GCPRs can signal through
multiple downstream effectors, only one pathway may be responsible for cell death. Different
inhibitors of these independent pathways were used to analyze effects of MTI-101 induced cell
death. Inhibition of CAM in combination with MTI-101 was found to exacerbate cell death
when compared to MTI-101 single treatment alone. A potential reason is that the negative
regulator of increased calcium levels CAM cannot balance the increased cytoplasmic calcium
and causes a further dysregulation of calcium that induces greater cell death. The CAM
inhibitor alone is not capable of inducing cell death, demonstrating this effect remains
dependent on the mechanism of MTI-101 signaling to induce greater cell death. In addition, a
CAM agonist known as CALP1 was able to block MTI-101 induced cell death. Activation of CAM
by binding calcium (or a calcium like protein, CALP1) has been found to bind to IP3 receptors
and inhibit depletion of ER stores and SOCE[19]. GPCRs are also capable of activating a Gs
subunit that uses cAMP as a second messenger, acting independently of the Gq pathway with
calcium. An AC inhibitor was used that prevents AC from converting ATP to cAMP for signal
transduction. The AC inhibitor combined with MTI-101 actively blocked cAMP formation, but
did not alter observed cell death. This indicates that MTI-101 induced cAMP activation is not
essential for cell death to occur.
The mechanism of GPCR signaling is still not fully understood as various combinations of
G-proteins coexist with various ligands and regulators that make this signal transduction
extremely complex. There are still orphan GPCRs that do not even have known ligands
currently. Based on these findings, MTI-101 is proposed to bind to a GPCR that activates a Gaq
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and a Gas subunit. The Gas subunit is capable of activating AC to generate elevated levels of
cAMP that appear to not be involved in MTI-101 induced cell death. The Gaq subunit activates
the PLC pathway responsible for increased cytosolic calcium. The negative regulator of calcium
signaling known as calmodulin was likely able to inhibit IP3R mediated store depletion and SOCE
entry but based on significance of calcium flux changes and when cell death occurred,
calmodulin is thought to play the greatest role in protection by the inhibition of SOCE.
Precedence of this finding with sustained calcium signaling induced by MTI-101 has been shown
with other drugs such as Fluoxetine. The selective serotonin reuptake inhibitor used to treat
depression known as fluoxetine has been shown deplete ER stores and elevate cytoplasmic
calcium through SOCE that lead to necrotic cell death via mitochondrial ATP depletion[20]. The
sustained calcium signaling induced by MTI-101 may be attributed to receptor endocytosis via
b-Arrestin that was found to be significantly higher in the drug sensitive WT cells. This may also
be a means of resistance found in PC-9R and H446-R as they have significantly decreased bArrestin expression.
Several frizzled receptors are significantly decreased in the resistant cells and are
retained down in the PC-9 RFD. Frizzled receptors have been shown to activate both calcium
and cAMP signaling when bound to agonists[21], [22]. In addition, frizzled receptors have been
shown to induce b-catenin nuclear localization used for the induction of EMT through increased
expression of TWIST and further repression of E-cadherin[23]. Treatment/resistance to MTI101 has previously been shown to reduce TWIST and E-cadherin expression in vitro and in vivo
along with prevention of nuclear localized b-catenin in vivo[16]. This combined data supports
that MTI-101 may be binding and activating a frizzled receptor that is down regulated in drug
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resistance. Further research is warranted to delineate the binding target of MTI-101. Genetic
manipulation of receptors with a GPCR Lenti-array CRISPR CAS9 library is an approach to
unbiasedly target individual GPCRs and determine if they remain vital in MTI-101 induced cell
death. The initial screen will analyze the effect of frizzled receptors expressed in these cell lines
and expand from there. Pharmacological inhibition of individual G-protein subunits combined
with MTI-101 could further support what G-protein subunits may be contributing to death as
well. Understanding the mechanism of MTI-101 could lead to optimized combination
treatment that target resistance along with the discovery of new drugs that target cell state and
cancer specific characteristics.

Conclusion
Overall, MTI-101 was found to induce necrotic cell death in lung cancer cells correlated
with concurrent calcium flux and cAMP activation. Resistance to MTI-101 was found to
decrease cationic channels, drug binding, and downstream signaling effectors such as calcium
and cAMP. A negative regulator of calcium, CAM, was found to exacerbate cell death when
inhibited, and block cell death when activated, illustrating its involvement in the mechanism of
MTI-101 induced cell death. In contrast, inhibition of AC and cAMP activity was found to have
no effect on MTI-101 induced cell death. A drug such as MTI-101 that has shown to selectively
target cancer cells and select for a population that decreases calcium signaling may alter cancer
cells to a less aggressive and more treatable cell state in the clinic to improve patient outcomes.
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Supplemental Materials
Supplemental Figure 1: b-Arrestin Significantly Decreased in MTI-101 Resistance (A) Fold
change of b-Arrestin expression between PC-9 and PC-9R using full genome RNA SEQ (B) Fold
change of b-Arrestin expression between H446 and H446-R using full genome RNA SEQ.
Supplemental Figure 2: CALP1 Protects from MTI-101 induced cell death up to 24 hours. PC-9
cells treated with MTI-101 or MTI-101+CALP1 for 24 hours and calculated cell viability of
percent viability compared to vehicle control via MTT assay. Error bars represent SEM
(significances denoted * for p<0.05, two-tailed T-test).
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Figure Legends
Figure 1: MTI-101 Resistance Blocks ER Calcium Flux Correlated with Cell Death (A) PC-9 WT
ER calcium flux compared to PC-9R over time in images with vehicle control, positive control
Thapsigargin, and treatment of MTI-101 (B) Percent death after MTI-101 treatment in Calcium
flux assay shows only PC-9 WT MTI-101 treatment cell death following calcium flux (C-E) PC-9
WT ER calcium flux cells over time comparing no treatment (negative vehicle control),
treatment with Thapsigargin (positive control) and MTI-101 (experimental group) in graphical
form (N=30) (F-H) PC-9R ER calcium flux cells over time comparing no treatment (negative
vehicle control), treatment with Thapsigargin (positive control) and MTI-101 (experimental
group) in graphical form (N=30).

Figure 2: MTI-101 Resistance Blocks Cytoplasmic Calcium Flux Correlated with Cell Death (A-C)
PC-9 WT cytoplasmic calcium flux cells over time comparing no treatment (negative vehicle
control), and MTI-101 (experimental group) in graphical form (N=30) (D-F) PC-9R cytoplasmic
calcium flux cells over time comparing no treatment (negative vehicle control) and MTI-101
(experimental group) in graphical form (N=30).

Figure 3: Transcriptome Analysis Indicates Decreased Cationic Channel Activity in Resistance
(A) Heatmap from RNA SEQ of differentially expressed cationic channels in PC-9 compared to
PC-9R (B-D) Individual cationic channel expression shows PC-9R expression of TRPC1, TRPC4,
and ORAI1 are significantly decreased compared to PC-9.
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Figure 4: MTI-101 Resistance is correlated with Decreased Drug Binding (A) A radiolabeled
MTI-101 binding assay found significantly decreased drug binding in PC-9R compared to PC-9
(N=3) (B) Significantly decreased drug binding was also found in H446-R compared to H446
(N=3). Reads in counts per minute (CPM) standardized by protein concentration (ug/uL). Error
bars represent SEM (significances denoted * for p<0.05, two-tailed T-test).

Figure 5: FAM-HYD1 binding Assay shows less drug binding in PC-9R and BEAS-2B cells
compared to PC-9. PC-9, PC-9R, and BEAS-2B cells were stained with WGA membrane dye
(RFP), FAM-HYD1 (GFP), and merged images (RFP+GFP) to visualize quantity and location of
drug binding.

Figure 6: MTI-101 Induces cAMP Activation that Remains Blocked in Resistance (A-C) PC-9 WT
cAMP activation using Flamindo2 cAMP indicator (YFP) in cells over time comparing no
treatment (negative vehicle control), 8-bromo cAMP (positive control), and MTI-101
(experimental group) in graphical form (N=30) (D-F) PC-9R cAMP activation in cells over time
comparing no treatment (negative vehicle control), 8-bromo cAMP (positive control), and MTI101 (experimental group) in graphical form (N=30).

Figure 7: Proposed Mechanism of MTI-101 in Lung Cancer. MTI-101 binds to and activates a
GPCR that is coupled intracellularly to a Gq and a Gs subunit. Gq generates the production of IP3
that binds to its receptor on the ER causing a depletion of ER stores. ER store depletion causes
STIM1 to dimerize and form a complex with SOCE channels that influx extracellular calcium into
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the cytoplasm. This overload of intracellular calcium from the ER and SOCE cause
mitochondrial calcium overload, ATP depletion, and loss of the mitochondrial membrane
potential leading to rapid necrotic cell death in lung cancer cells. The Gs signaling pathway is
also proposed to be activated by MTI-101 causing the generation of cAMP that is not involved
in the rapid drug induced cell death.

Figure 8: MTI-101 Death is not Correlated with Death through cAMP Activation (A) Model of
cell permeable AC inhibitor’s role in MTI-101 signaling. The AC inhibitor (SQ22536) binds
downstream of MTI-101 induced GPCR activation to AC to prevent ATP conversion to cAMP (B)
PC-9 WT cAMP activation using Flamindo2 cAMP indicator (YFP) in cells over time comparing no
treatment (MTI-101 negative control), AC Inhibitor (combination treatment negative control),
8-bromo cAMP (MTI-101 positive control), and MTI-101 (experimental group 1) and AC
Inhibitor/MTI-101 combination treatment (experimental group 2) in graphical form (N=30) (C)
Percent death of cAMP assay comparing no treatment (MTI-101 negative control), AC inhibitor
(combination treatment negative control), MTI-101 treatment (experimental group 1), and AC
Inhibitor/MTI-101 combination treatment (experimental group 2).

Figure 9: MTI-101 Death is Correlated with Death through Calcium Flux Modulated by
Calmodulin (A) Model of cell permeable CAM agonist (CALP1) and its role in MTI-101 signaling.
The CAM agonist binds to CAM to induce its active conformation and negatively regulate
calcium flux by binding to IP3R to prevent IP3 binding and ER store depletion along with
inhibition of SOCE channel opening (B) Model of cell permeable CAM Inhibitor (W7) binds to
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CAM to stabilize its inactive conformation and prevents calcium binding that can no longer
participate in the negative regulation of calcium flux within cells (C) Percent death of calcium
flux assay comparing no treatment (MTI-101 negative control), CAM agonist (combination
treatment negative control), MTI-101 treatment (experimental group 1), and CAM agonist/MTI101 combination treatment (experimental group 2) (D) Percent death of calcium flux assay
comparing no treatment (MTI-101 negative control), CAM inhibitor (combination treatment
negative control), MTI-101 treatment (experimental group 1), and CAM inhibitor/MTI-101
combination treatment (experimental group 2).

Figure 10: CAM Agonist Partially Protects from MTI-101 Induced Calcium Flux (A) Single cell
analysis and (B) N=30 of ER calcium fluctuations using R-CEPIA1er in PC-9 cells comparing
negative vehicle control, MTI-101 treatment, and CAM agonist/MTI-101 combination treatment
(C) Single cell analysis and (D) N=30 of cytoplasmic calcium fluctuations using X-Rhod-1 AM in
PC-9 cells comparing negative vehicle control, MTI-101 treatment, and CAM agonist/MTI-101
combination treatment.

Figure 11: CAM Inhibitor Does Not Significantly Alter MTI-101 Induced Calcium Flux. Analysis
of cytoplasmic calcium fluctuations using X-Rhod-1 AM in PC-9 cells comparing negative vehicle
control, MTI-101 treatment, and CAM agonist/MTI-101 combination treatment (N=30).
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Figure 12: Evidence for Frizzled Receptor as MTI-101 Binding Target. Heat map using full
genome RNA SEQ comparing differentially expressed GPCR genes between PC-9, PC-9 RFD, PC9R, H446, and H446-R.
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Chapter 5

Conclusion and Future Directions
Conclusion
Lung cancer remains the leading cause of death from all cancers, but recent discoveries
and earlier detection methods have improved therapy options along with patient survival[1].
Education and prevention of smoking has also contributed to the recent decline in cases over
the years[2]. The heavy mutational burden coupled with tumor heterogeneity enables lung
cancer to maintain drug resistance despite advances in novel therapy options. Furthermore,
late-stage detection in lung cancer enhances the tumor’s capability of evading treatment.
Current therapy options target common mutational drivers such as EGFR or KRAS (i.e.,
osimertinib and sotorasib) as well as systemic chemotherapy options such as etoposide and
cisplatin. Recent advances have also been made in the incorporation of immunotherapies to
target lung cancer such as pembrolizumab. Selectively targeting markers or attributes for lung
cancer may prove to be only half the battle as drug resistance and metastasis still remain the
prominent causes of relapse. Targeting or reversing cell state may be the solution to treatment
of late-stage and/or drug resistant tumors.
A cyclic peptide, derived from a less potent linear parental compound HYD1, known as
MTI-101, was found to selectively target cancer cells and induce genotypic and phenotypic
changes consistent with a more epithelial like cell. Given HYD1 was originally found in a high
throughput screen that blocked cell adhesion, MTI-101 resistance could explain this attribute
with decreased fibronectin expression along with increased anoikis sensitivity. MTI-101 may
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select for a population that reduces cell-ECM connections and relies heavily on cell-cell
connections to maintain survival (more sensitive to anoikis) and therefore creates a less stiff
tumor population that become less invasive and more treatable. Cell-ECM connections are an
integral part of tumorigenesis and malignancies that cause increased stiffness in cancer[3].
Decreased cell-ECM connections (fibronectin, laminin, collagen) in conjunction with increased
cell-cell connections (claudins, occludins, E-cadherin) have been connected with a less stiff
cancer type that displays decreased invasiveness and tumor aggressiveness[3]. MTI-101 could
block cell adhesion with the ECM (decrease in fibronectin) and increase cell-cell connections
with E-cadherin allowing for a less stiff phenotype. Tumor stiffness relies on excessive calcium
signaling[4] which MTI-101 was also found to select for attenuated calcium, consistent with
decreased tumor stiffness. Prolonged exposure to MTI-101 induced phenotypic cell alterations
including decreased mesenchymal protein expression, increased epithelial protein expression,
inability to invade in Matrigel, increased epithelial morphology, increased sensitivity to anoikis,
and inability to form distal tumor sites in vivo. These in vitro and in vivo models provide
substantial evidence to confer a change in cell state within cancer cells to a more favorable MET
phenotype, independent of mutational driver, with the sole pressure of MTI-101.
MTI-101 is suspected to selectively target cancer cells exposing a vulnerability of
mutations acquired by malignant cells that downregulated calcium homeostasis pathway genes
to accommodate proliferation and migration. A healthy bronchial epithelial cell line known as
BEAS-2B was found to have minimal cytotoxic effects when treated with the same lethal dose
of MTI-101 as the lung cancer cell lines. Resistance to MTI-101 in lung cancer cells was found to
decrease cation channel expression such as TRPC1, TRPC4, and ORAI1 which has been
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previously reported to play a role in MTI-101 induced cell death[5]. Treatment with MTI-101
was shown to decrease ER calcium stores while increasing cytoplasmic calcium levels.
Concurrently, MTI-101 was reported to generate cAMP in a second signaling pathway. The
simultaneous activation of calcium flux and cAMP alludes to the activation of a GPCR on the
plasma membrane. Interestingly, resistance to MTI-101 blocked this calcium flux and cAMP
generation concluding that cellular modifications are taking place upstream of these signaling
pathways. Decreased MTI-101 drug binding in resistance conferred that MTI-101’s target may
be mutated, knocked down, or not trafficked to the membrane.
Given GPCRs’ have the capability of signaling through multiple G-protein subunits, the
rapid death induced by MTI-101 may be attributed to only one G-protein signal transduction.
Inhibition of AC was found to block cAMP generation with MTI-101 treatment but was not able
to protect from death. In contrast, a calmodulin agonist was able to reduce MTI-101 induced
calcium flux and protect from cell death. In addition, inhibition of calmodulin was reported to
exacerbate cell death. While activated calmodulin was able to delay/decrease overall ER store
depletion as reported in the literature by binding to the IP3R and competitively inhibiting IP3[6],
the effect of calmodulin activation with cytoplasmic calcium levels was suspected to be more
significant in respect to cell death and likely the main source of protection. Activated
calmodulin by calcium has been reported in the literature to impede SOCE channels on the
plasma membrane[7]. Resistance to MTI-101 has been shown to downregulate SOCE proteins
such as TRPC1, TRPC4, and ORAI1 which may have the same negative regulation of calcium flux
seen with a calmodulin agonist that is capable of protecting from cell death. It may also be that
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the receptors responsible for this signal transduction pathway may be downregulated in
resistance and the need for these proteins is no longer as essential.
The ultimate goal for any drug discovery process is to analyze and develop a drug that
can safely be administered in the clinic with a positive therapeutic outcome. Understanding
mechanisms or resistance along with combined efficacy among standard of care agents remains
crucial in mobilizing a drug past pre-clinical models. Standard of care agents such as
osimertinib and cisplatin have been reported to have synergism when combined with MTI-101
treatment. In addition, MTI-101 resistant lung cancer cells have shown collateral sensitivity to
single treatment of standard of care agents. Given treatment with standard of care agents for
lung cancer have been reported to induce EMT, and MTI-101 has been shown to induce MET,
these combined treatments may be vital in double bind studies to target varying attributes in
cell state[8]. This combination strategy may alleviate drug resistance commonly presented in
single agent treatment and improve patient survival rates. Further research into the
mechanism of MTI-101 induced cell death in lung cancer is needed to determine its role in MET
along with its clinical applications.
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Future Directions
The MTI-101 induced change in cell state to a more epithelial like phenotype provides
characteristics and transcription factors that could lead to the development of future drug
targets in lung cancer. The RNA SEQ database comparing WT to resistance in MTI-101 could be
mined for further delineation of factors modulating the cell state transition. Drugs that inhibit
or induce these factors could result in a sustained transition as seen in the RFD cell line.
TWIST1 and TWIST2 were found to be promising targets of inducing EMT in the WT cancer cells.
There are currently small molecules in preclinical stages such as berberine hydrochloride and
thymoquinone that have been shown to target and inhibit TWIST[9]. Using these molecules in
combination with standard of care agents such as osimertinib and erlotinib could prove to have
synergistic effects with lung cancer treatment as seen with MTI-101 combination therapy. The
gene signature may also inform decisions on targeting calcium pathways in lung cancer given
MTI-101 resistance selects for attenuation of calcium signaling that could be playing a role MET.
Small peptides that inhibit calcium signaling such as SOCE channel inhibitors in lung cancer[10]
may be investigated in combination with standard of care agents to illustrate a potential
combination strategy for cancer treatment.
Evidence suggests that MTI-101 activates a GPCR on the plasma membrane that induces
calcium overload leading to cell death. An unbiased approach in attempt to delineate the
binding target of MTI-101 would be a GPCR library screen. A Lenti-Array GPCR Crispr library
containing gRNAs to knock out 435 different GPCRs will be analyzed with effects on MTI-101
treatment. Endpoints of death will be observed, and positive hits will be GPCR knockouts that
confer resistance to lethal WT cancer cell doses of MTI-101. Positive hits will further be
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screened by drug binding assays, calcium flux assays, and MTTs with treatment of standard of
care agents. While a library screen is one method to determine the MTI-101 binding target, it
implies that there is only one target of MTI-101 and no compensatory mechanisms are
involved. Another approach would be to further delineate signaling pathways involved in MTI101 induced cell death.
Natural ligands of GPCRs typically do not lead to cell death, so how is MTI-101 different?
The literature suggests that sustained activation of GPCRs can lead to necrosis, autophagy, and
apoptosis[11]. There are several explanations to GPCR sustained signaling. First, synthesized
ligands have been created to bind in a different manner to a GPCR than their natural ligand.
Ligands that irreversibly bind to a GPCR via covalent linkage or bind with a higher affinity have
been shown to have sustained activity on the receptor. For example, fingolimod is a synthetic
compound that has been shown to bind to sphingosine-1-phosphate (S1P) receptor (GPCR) at a
higher affinity than its natural ligand S1P to produce a sustained signal through Gai after
internalization[12]. Activated GPCRs are subjected to phosphorylation and receptor mediated
endocytosis with the recruitment of b-arrestins[13]. b-arrestins were found to be
overexpressed in both WT cells compared to their respective MTI-101 resistant cell lines. The
overexpression of b-arrestin has been shown to induce EMT by increasing cell signaling
responsible for proliferation and motility[13]. b-arrestin inhibitors have been developed and
shown to decrease receptor mediated endocytosis signaling such as sustained cAMP
generation[14],[15]. Combination treatment with b-arrestin inhibitors with MTI-101 may
delineate if sustained calcium signaling is enabled by receptor mediated endocytosis.
Pharmacological inhibition or genetic manipulation of G-protein subunits may also be
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implemented to examine the role of the different G-proteins. Given MTI-101 is proposed to
induce cell death via calcium overload, a Gaq inhibitor or knockout will provide a valuable
starting point. Since GPCRs are involved in most phycological communications on the cell
membrane, ablation of entire G-protein subunits could produce unintended consequences for
the cells. A healthy control that is not sensitive to MTI-101 such as BEAS-2B should also be
subjected to the same G-protein knockdown or knockout to remedy these concerns.
MTI-101 has been described here to show promising effects in combination with lung
cancer standard of care agents. Osimertinib, Erlotinib and Cisplatin all induce EMT driven
resistance in the clinic. Meanwhile, MTI-101 has been shown to induce MET characteristics in
vitro and in vivo. A double bind strategy alternating between MTI-101 and standard of care
agents may be implemented to understand if evolving resistance to one drug enhances
sensitivity to the other and prolong survival. A pilot study should be conducted to understand
at what point MTI-101 treatment changes EMT markers within tumors. This time point will
establish the intervals between the two treatments. Alternation of treatment with MTI-101
with standard of care agents may provide an extended window for subsequent treatments and
ultimately prolong survival.
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